

European S2k Guideline on Chronic Pruritus

In cooperation with the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV)

Elke WEISSHAAR¹, Jacek C. SZEPIETOWSKI², Florence DALGARD^{3,4}, Simone GARCOVICH⁵, Uwe GIELER⁶, Ana GIMENEZ-ARNAU⁷, Julien LAMBERT⁸, Tabi LESLIE⁹, Thomas METTANG¹⁰, Laurent MISERY¹¹, Ekin SAVK¹², Markus STREIT¹³, Erwin TSCHACHLER¹⁴, Joanna WALLENGREN¹⁵ and Sonja STÄNDER¹⁶

¹Department of Clinical Social Medicine, Environmental and Occupational Dermatology, Ruprecht-Karls-University, Heidelberg, ²Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland, ³Department of Dermatology and Venereology, Skåne University Hospital, Lund University, Malmö, Sweden, ⁴National Centre for Dual Diagnosis, Innlandet Hospital Trust, Brumundal, Norway, ⁵Institute of Dermatology, F. Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Giessen, Germany, ⁷Department of Dermatology, Hospital del Mar – Institut Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain, ⁸Departments of Dermatology: ⁸University Hospital of Antwerp, University of Antwerp, Belgium, ⁹Royal Free Hospital, London, UK, ¹⁰DKD Helios, Wiesbaden, Germany, ¹¹University Hospital Brest, France, ¹²Adnan Menderes University, Aydin, Turkey, ¹³Kantonsspital, Aarau, Switzerland and ¹⁴Medical University, Vienna, Austria, ¹⁵Department of Clinical Sciences Lund, Dermatology and Venereology, Lund University, Skåne University Hospital, Lund, Sweden, and ¹⁶Center for Chronic Pruritus, Department of Dermatology, University Hospital Muenster, Germany

Corr: Elke Weisshaar, MD, Occupational Dermatology, Department of Dermatology, Ruprecht-Karls University Heidelberg, Voßstr. 2, DE-69115 Heidelberg, Germany. E-mail: elke.weisshaar@med.uni-heidelberg.de

Abbreviations and explanations

AD:	Atopic dermatitis	PAR:	Proteinase-activated receptor
AEP:	Atopic eruption of pregnancy	PBC:	Primary biliary cirrhosis
CGRP:	Calcitonin gene-related peptide	PEP:	Polymorphic eruption of pregnancy
CKD:	Chronic kidney disease	PG:	Pemphigoid gestationis
CNS:	Central nervous system	Pruritus:	A skin sensation that elicits the urge to scratch
CNPG:	Chronic nodular prurigo	PUO:	Pruritus of undetermined origin
CP:	Chronic pruritus (longer than 6 weeks)	PTH:	Parathyroid hormone
CPG:	Chronic prurigo	PV:	Polycythaemia vera
CSU:	Chronic spontaneous urticaria	RCT:	Randomised controlled trials
DIF:	Direct immunofluorescence	SSRI:	Selective serotonin re-uptake inhibitors
ICP:	Intrahepatic cholestasis of pregnancy	TRP:	Transient receptor potential
IFSI:	International Forum on the Study of Itch	UP:	Uremic pruritus
IIF:	Indirect immunofluorescence	UV:	Ultraviolet
IL:	Interleukin	VAS:	Visual analogue scale
Itch:	Synonym of pruritus	VIP:	Vasoactive intestinal peptide
NRS:	Numerical rating scale	VRS:	Visual rating scale
NSAID:	Non-steroidal anti-inflammatory drugs		

CONTENTS

1.	The challenge of writing this guideline	471
2.	Definitions and clinical classification	471
3.	Epidemiology of chronic pruritus	472
4.	The clinical picture of chronic pruritus	472
4.1		472
4.1.1	Chronic Pruritus in lesional and non-lesional skin	472
4.1.2	Pruritus in kidney disease	473
4.1.3	Pruritus in hepatobiliary diseases (cholestatic pruritus)	473
4.1.4	Pruritus in metabolic and endocrine diseases	473
4.1.5	Pruritus in malignancy	473
4.1.6	Pruritus in infectious diseases	474
4.1.7	Pruritus in neurological diseases	474
4.1.8	Pruritus in psychiatric diseases	474
4.1.9	Drug-induced chronic pruritus	475
4.2	Specific patient populations	475
4.2.1	Chronic pruritus in the elderly	475
4.2.2	Chronic pruritus in pregnancy	475
4.2.3	Chronic pruritus in children	476
5.	Diagnostic management	476
5.1	Patient history and clinical examination	476
5.2	Diagnostic algorithm and diagnostics	478
6.	Therapy	478
6.1	Therapy: general principles including emollients	478
6.2	Causative therapy and aetiology-specific treatment	480
6.3	Topical therapy	481
6.3.1	Local anaesthetics	481
6.3.2	Zinc, menthol and camphor	482
6.3.3	Capsaicin	482
6.3.4	Topical glucocorticosteroids	483
6.3.5	Tacrolimus and pimecrolimus	483
6.3.6	Acetylsalicylic acid	483
6.3.7	Doxepin	483
6.3.8	Topical mast cell inhibitors	484
6.4	Systemic therapy	484
6.4.1	Antihistamines	484
6.4.2	Mast cell inhibitors	485
6.4.3	Glucocorticosteroids	485
6.4.4	Opioid receptor agonists and antagonists	485
6.4.5	Gabapentin and pregabalin	486
6.4.6	Antidepressants	486
6.4.7	Serotonin receptor antagonists	487
6.4.8	Thalidomide	487
6.4.9	Leukotriene receptor antagonists and TNF α antagonists	487
6.4.10	Cyclosporine, methotrexate, azathioprine and tacrolimus	487
6.4.11	Neurokinin receptor 1 antagonist	488
6.4.12	Biologics	488
6.4.13	Physical treatment modalities	488
6.5	Ultraviolet phototherapy	489
6.6	Treatment in special populations	490
6.6.1	Treatment of chronic pruritus in the elderly	490
6.6.2	Treatment of chronic pruritus in pregnancy	491
6.6.3	Treatment of chronic pruritus in children	491
6.7	Psychosomatic therapy (relaxation techniques and psychotherapy)	492
7.	Key summary of discussion	492
8.	References	493

Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis patients to 100% in skin diseases such as urticaria and atopic dermatitis (AD). Pruritus may be the result of a dermatological or non-dermatological disease. Especially in non-diseased skin it may be caused by systemic, neurological or psychiatric diseases, as well as being a side effect of medications. In a number of cases chronic pruritus may be of multifactorial origin. Pruritus needs a precise diagnostic work-up. Management of chronic pruritus comprises treatment of the underlying disease and topical treatment modalities, including symptomatic antipruritic treatment, ultraviolet phototherapy and systemic treatment. Treating chronic pruritus needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. We present the updated and consensus based (S2k) European guideline on chronic pruritus by a team of European pruritus experts from different disciplines. This version is an updated version of the guideline that was published in 2012 and updated in 2014 (www.euroderm.org).

1. THE CHALLENGE OF WRITING THIS GUIDELINE

Chronic pruritus (CP) is a frequent symptom in the general population and in many skin and systemic diseases (1). Due to its severity and the fact that it is frequently refractory to therapy, it causes a high burden and impairs quality of life. This guideline addresses all causes and types of CP including chronic prurigo. In its early stage, CP is considered a symptom of the underlying disease. However, with time, CP may develop its own dynamics that are no longer linked to the course of the underlying disease. In this stage, and much like chronic pain, this can be considered a distinct syndrome (CP syndrome) or even a disease in its own right. The observation that different patients with CP report similar severity, course and burden of CP despite the diversity of the underlying origins supports the view that CP requires independent consideration. Nevertheless, this guideline presents a diagnostic and therapeutic approach that is applicable to all types of CP. However, as a consequence of the diversity of possible underlying diseases, each form of CP should also be considered individually. Studies have demonstrated that early intervention in certain types of CP may lead to a significant improvement [e.g. therapy of polycythemia vera-associated aquagenic pruritus with janus kinase (JAK) inhibitors].

Still, there is a significant lack of randomised controlled trials (RCTs) investigating different types of CP in detail, which can be explained by the diversity and complexity

of this symptom, the multifactorial aetiologies of pruritus and the lack of well-defined outcome measures, biomarkers and therapy targets. To complicate matters, RCTs exist for some types of pruritus, but with conflicting results. However, new therapies for improved medical care have been suggested and are summarised in this guideline. Expert recommendations are also provided. In addition, if the underlying cause is detected, disease-specific guidelines should be consulted [e.g. atopic dermatitis (AD) (2–5), urticaria (6), scabies (7), adult palliative care (8)]. The health care systems in many countries and their social economic situation with ever diminishing financial resources increase the need for guidelines. These recommendations are based on a consensus of participating countries, while also allowing for adaptation to country-specific treatment modalities and health care structures. Furthermore, it should be borne in mind that several topical and systemic therapies can only be prescribed “off-label” and require informed consent. If such “off-label” therapies cannot be initiated in the physician’s office, cooperation with a specialised centre for pruritus might be helpful. The guideline addresses all medical disciplines that work with patients suffering from CP.

This updated and revised guideline considers the Appraisal of Guideline Research and Evaluation Instrument (AGREE 2015) and the methods of the GRADE working group (www.gradeworkinggroup.org). All consented recommendations are written at the end of each section on treatment in Section 6.

2. DEFINITIONS AND CLINICAL CLASSIFICATION

The definitions presented in this guideline are based on the terminology defined by the International Forum for the Study of Itch (IFSI). The European participants of this guideline agreed to use this terminology. All contributors accept pruritus and itch to be synonymous. This guideline also defines pruritus/itch as a sensation that provokes the desire to scratch. Patients do not only scratch; they also rub, pinch or damage their skin with devices (all summarised from this point onward under the term scratching). In some diseases involving itch, patients’ scratching does not lead to skin damage (e.g. urticaria); in other diseases, scratching leads to a worsening of itch (e.g. urticaria factitia) and is accordingly avoided. These differences hinder scratching or scratch lesions from serving as common objective markers for the severity of itch.

According to the IFSI, CP is defined as pruritus lasting 6 weeks or longer (9). This is a practical distinction defined by clinicians in order to facilitate the decision to perform a diagnostic work-up. In some cases, pruritus may precede the diagnosis of the underlying disease by years (premonitory pruritus); in others, it is the early sign of a neoplastic disease such as Hodgkin lymphoma (paraneoplastic disease). In line with the IFSI, the term

“pruritus sine materia” will not be used in this guideline (10). In patients with no identified underlying disease, the term “pruritus of unknown origin” or “pruritus of undetermined origin” (PUO) is used. The term “pruritus of unknown aetiology” should be avoided as in most clinically well-defined forms of pruritus the neurobiological mechanisms of CP are unknown [e.g. chronic kidney disease (CKD)-associated pruritus].

The IFSI classification comprises a clinical distinction of patients with Group I pruritus on primarily diseased/inflamed skin, Group II pruritus on normal skin and Group III pruritus with chronic secondary scratch lesions (9). According to this classification, the aetiology of CP is classified into categories as “dermatological”, “systemic”, “neurological”, “somatoform”, “mixed origin” and “others” (9). Neurological pruritus refers mostly to diseases involving the central and/or peripheral nervous system resulting in diseased or malfunctioning neurons firing action potentials with origins at any point along the afferent pathway (11, 12). In most cases, this is better described as neuropathic pruritus inducing an overlap of pain, pruritus and par- or dysaesthetic sensations. Somatoform pruritus is defined as pruritus where psychic, psychiatric and psychosomatic factors play a critical role in the onset, intensity, aggravation or persistence of the pruritus.

3. EPIDEMIOLOGY OF CHRONIC PRURITUS

Data on the prevalence of CP is very limited. The prevalence of CP seems to increase with age (13), but epidemiological studies are lacking. It is estimated that about 60% of the elderly (over 65 years of age) suffer from mild to severe occasional pruritus every week (14), referred to as pruritus in the elderly. A population-based cross-sectional study in 19,000 adults showed that about 8–9% of the general population experienced acute pruritus, which was a dominant symptom across all age groups (15). Moreover, it was revealed that pruritus is strongly associated with chronic pain (16). Recent surveys indicate a point prevalence of CP to be around 13.5% in the general adult population (17, 18) and 16.8% in employees seeking early detection cancer screenings (19). The 12-month-prevalence of CP was 16.4% and its lifetime prevalence 22.0% in a German population-based cross-sectional study (17). All these data suggest a higher prevalence of CP in the general population than previously reported (17). For the first time, a recent study found a 12-month cumulative incidence of CP of 7% and incident pruritus was significantly associated with higher age (18). Multivariate analysis revealed eczema, dry skin, asthma, liver disease, an elevated body mass index and higher anxiety scores to be determinants of prevalent CP (18).

CP may be due to both dermatological and systemic diseases. However, the origin of pruritus is unknown in

up to 20% of affected patients (1). For example, pruritus is present in all patients with AD and urticaria (20) and in about 80% of psoriatic patients (21, 22). Systemic diseases such as primary biliary cirrhosis (PBC) and CKD are associated with CP in 80–100% and 25–70%, respectively (23); however, the great variability of numbers may be explained by a lack of disease definition and prevalence estimates. The first representative cohort study investigating CP in haemodialysis patients showed 25.2% to suffer from CP (point prevalence), while the lifetime prevalence was 35.2% (24). Pruritus is a frequent symptom in patients with Hodgkin’s lymphoma, occurring in more than 30% of this patient group (1). In a retrospective study on 139 patients with CP, most cases of severe and long-lasting itch were found in patients with multiple systemic diseases and in patients with pruritus of unknown origin, while pruritus of the scalp and face was often a presenting symptom of psychiatric disease (25).

Only few studies have addressed the frequency of pruritus in primary care. According to the Australian BEACH Program, a continuous national study of general practice activity, pruritus was the presenting complaint for 0.6% of consultations, excluding perianal, periorbital or auricular pruritus (26). In the UK, the fourth national study of morbidity statistics from general practice (27) was conducted in 1991/1992 with 502,493 patients (1% sample of England and Wales), resulting in 468,042 person-years at risk. Pruritus and related conditions were present in 1.04% of consultations (male, 0.73%; female, 1.33%). In Crete, where patients with cutaneous disorders mostly present to hospitals rather than to primary care centres, PUO was diagnosed in 6.3% of 3,715 patients in 2003 (28). In Germany and the Netherlands the prevalence of pruritus as a reason for consultation in primary care resulted in approximately 0.7% of all consultations, most of these resulting in a diagnosis of skin disease (SESAM2 study from 1999–2000, unpublished data from the Dutch Transition project from 1995 to 2003) (29).

The reader is referred to Section 4.2 for a more detailed discussion of the epidemiology of CP in specific patient populations.

4. THE CLINICAL PICTURE OF CHRONIC PRURITUS

4.1.1. Chronic pruritus in lesional and non-lesional skin.

CP may occur as a common symptom in patients with dermatoses with primary skin lesions and systemic, neurologic and psychiatric/psychosomatic diseases without primary skin lesions (9). In the 3 latter instances, the skin may appear normal or have skin lesions induced by scratching. In chronic and severe cases, patients can develop chronic prurigo (CPG), which may present as chronic nodular prurigo (CNPG) or other subtypes (30). In these cases, a clinical diagnosis is difficult to establish and diagnostics should be performed. Systemic diseases

frequently accompanied by pruritus are summarised in **Table I**. In recent years, several entities of pruritus on inflamed and normal skin have been characterised in more detail. Some frequent patient populations and systemic diseases inducing CP are presented in the following sections.

4.1.2. Pruritus in kidney disease. The pathophysiology of CKD-associated pruritus is unknown. Implicated mechanisms have included direct metabolic factors: increased concentrations of divalent ions (calcium, magnesium), parathyroid hormone (PTH), histamine and tryptase, dysfunction of peripheral or central nerves, the involvement of opioid receptors (μ - and κ -receptors) and xerosis cutis (dry skin) have been suggested as likely candidates (31–39). Some data point to a possible role for micro-inflammation, which is relatively frequent in uraemia (31, 40). Two uremic toxins, p-cresylsulfate and indoxylsulfate, were recently suggested to be involved in the pathogenesis of CP in kidney disease (41).

One representative study on CP in 177 haemodialysis patients showed that 43.5% had normal looking skin (IFSI II), 37.9% had secondary scratch lesions including CPG (IFSI III) and 18.6% had a skin disease (IFSI I) (42).

4.1.3. Pruritus in hepatobiliary diseases (cholestatic pruritus). CP is a frequent symptom in patients with hepatobiliary disease and cholestasis due to mechanical obstruction, metabolic disorders or inflammatory diseases (43–45). It is termed cholestatic pruritus (ChP), although cholestasis is not a prerequisite of pruritus related to diseases of the liver. ChP may be quite severe and can even precede the diagnosis of, e.g. primary biliary cholangitis (PBC) by years (46, 47). Pruritus is less frequent in patients with infectious liver disease (hepatitis B or C) or toxic liver disease (e.g. alcohol-induced). The true prevalence of CP in hepatobiliary diseases is not known due to lacking epidemiological data. It seems that CP is most frequent in PBC, primary sclerosing cholangitis (PSC) and secondary sclerosing

cholangitis (SSC). CP usually peaks in the evening and night, frequently presenting without any primary skin lesion but sometimes with secondary scratch lesions and CPG. It is often generalised, affecting palms and soles in the early stage (48).

It has recently been shown that increased serum autotaxin (ATX) [the enzyme that metabolises lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA)] levels, and thereby increased LPA levels, are specific for pruritus in cholestasis, including intrahepatic cholestasis of pregnancy and paediatric cholestatic disorders (44, 45, 47), but not for other forms of systemic pruritus (49). Rifampicin significantly reduced itch intensity and ATX activity in pruritic patients. The beneficial antipruritic action of rifampicin may be explained partly by pregnane X receptor (PXR)-dependent transcription inhibition of ATX expression (49). Successful treatment with μ -receptor opioid antagonists such as nalmefene and naltrexone supports the hypothesis that opioid receptors and a high opioid tone influences ChP (50).

4.1.4. Pruritus in metabolic and endocrine diseases. In endocrine disorders such as hyperthyroidism and diabetes mellitus, less than 10% of patients report pruritus (51, 52). In patients with hypothyroidism, pruritus is most probably driven by xerosis of the skin. Patients with primary hyperparathyroidism do complain of itch in a substantial number of cases (53). The pathophysiology of pruritus in primary hyperparathyroidism is not known. These patients often experience a lack of vitamin D and minerals (e.g. zinc etc.), which probably contributes to CP. Iron deficiency may be associated with CP (54). The mechanism for this is unknown. Iron overload as in haemochromatosis may lead to CP (55, 56). CP in metabolic and endocrine disease frequently occurs as generalised pruritus, but localised forms such as genital CP may occur, e.g. in diabetes mellitus (51, 57). The clinical picture is not specific, frequently accompanied by dry skin and sometimes showing secondary scratch lesions (IFSI III) (1).

4.1.5. Pruritus in malignancy. Several malignant disorders including tumours, bone marrow diseases, myeloproliferative and lymphoproliferative disorders may be accompanied by pruritus. The term “paraneoplastic pruritus” is used to describe pruritus in patients with cancer (58). The true frequency of this symptom in malignant disease is unclear and epidemiological data in this field are limited. One study in a cohort of cancer patients showed that 5.9% suffer from generalised itch (59). Gastrointestinal tumours and haematological malignancies were among the tumours that most commonly cause pruritus (59). Most of the patients affected do not exhibit specific dermatoses, but unaffected skin or non-specific eruptions with and without papules and excoriations. In general, the prevalence of pruritus in haematological malignancies is higher compared to

Table I. Systemic diseases that can induce pruritus (examples)

Metabolic and endocrine diseases	<ul style="list-style-type: none"> • Chronic kidney disease (CKD) • Hepatobiliary diseases with or without cholestasis • Hyperparathyroidism • Hyper- and hypothyroidism • Iron deficiency • Diabetes mellitus
Infective diseases	<ul style="list-style-type: none"> • HIV and AIDS • Parasitoses including helminthosis • Viral hepatitis
Haematological disorders	<ul style="list-style-type: none"> • Polycythemia vera, myeloproliferative diseases • Lymphoma, e.g. Hodgkin lymphoma
Neurological diseases	<ul style="list-style-type: none"> • Multiple sclerosis • Brain tumours • Notalgia paraesthetica • Brachioradial pruritus • Postherpetic neuralgia • Small-fibre neuropathies
Psychiatric or psychosomatic diseases	<ul style="list-style-type: none"> • Depression • Anxiety • Delusional disorders • Eating disorders

non-haematological malignancies; it is estimated to be around 30% in Hodgkin lymphoma, around 15–50% in non-Hodgkin lymphoma and around 15–50% in polycythemia vera (PV) (58, 60). The mechanisms of pruritus in malignancy are still not understood. Several mediators and mechanisms have been discussed in the literature such as toxic products generated by the tumour itself, allergic reactions to compounds released and a direct affect on the brain or nerves (in brain tumours), the latter being referred to as neuropathic pruritus (14, 61). Recently, interleukin-31 (IL-31), a Th-2 cytokine, was found to be highly associated with itch in lymphoma and highly expressed in malignant T-cells (62). In PV, more than 50% of patients suffer from pruritus (60, 63, 64). Aquagenic pruritus with pinching sensations after contact with water is a characteristic but not necessary feature. It has been suggested that high levels of histamine released by the augmented numbers of basophilic granulocytes might trigger the itch (65). For PV this seems to be most pronounced in patients showing the JAK2 617V mutation (60, 66).

Pruritus in Hodgkin's disease often starts on the legs and is most severe at night, but generalised pruritus soon ensues. Several factors such as secretion of leukopeptidases and bradykinin, histamine release and high IgE levels with cutaneous depositions may contribute to pruritus in lymphoma (67). Patients with carcinoid syndrome may experience pruritus in addition to flushing, diarrhoea and cardiac symptoms (68).

A recent population-based cohort study in 8,744 patients with CP showed that CP without concomitant skin changes is a risk factor for undiagnosed haematological and bile-duct malignancy (69). A nationwide Danish cohort study based on registry data showed a 1-year absolute cancer risk of 1.63%, and a 13% higher than expected number of both haematological and various solid cancers among patients with pruritus was found. This related in particular to haematological cancers, above all Hodgkin lymphoma (70); however, the study was unable to differentiate between acute and chronic itch.

4.1.6. Pruritus in infectious diseases. Acute or chronic pruritus may occur with skin infections and infestations, among which scabies is the most prominent example (71). Viral infections such as herpes simplex, herpes zoster and varicella can present with acute pruritus. CP may occur in 4% of herpes zoster patients, which is termed post-herpetic itch (1).

Some generalised infections are accompanied by pruritus. Above all, patients infected with human immunodeficiency virus (HIV) may develop CP, which can be the initial presentation of HIV infection. The true prevalence is not known but could be as high as 45% according to cross-sectional study (72). In a significant number of HIV patients itching has no detectable cutaneous or systemic cause; however, HIV patients are prone

to develop pruritic papular eruption (PPE), a major cause of CP in African HIV patients (1, 73). There is evidence for a high association between prurigo and HIV infection, but regional variations need to be considered (73).

Whether toxocariasis infections lead to pruritus in a substantial number of patients remains to be confirmed (74). Pruritus has been reported in up to 15% of patients with chronic hepatitis C virus (HCV) infection and may be a presenting symptom (75).

4.1.7. Pruritus in neurological diseases. Space occupying lesions (tumours, abscesses, haemorrhage) of the nervous system and degenerative neurological diseases, e.g. multiple sclerosis, are rare causes of neuropathic pruritus with variable clinical presentation (76–79). Pruritus due to these neurological disorders may be the presenting symptom prior to diagnosis and could be transient, continuous or paroxysmal in nature (80). Entrapment syndromes of specific peripheral nerves such as notalgia paraesthetica, brachioradial pruritus, cheiralgia paraesthetica and meralgia paraesthetica present with pruritus localised to a specific anatomical area (81–85). A typical accompanying clinical finding is the presence of various paraesthetic sensations, including a feeling of electrical current, prickling, tingling, burning and numbness. A recently recognised clinical phenomenon is generalised pruritus triggered by a localised neurological disorder, e.g. brachioradial pruritus (86, 87). In a broader perspective, neuropathy of small cutaneous nerve fibres in dermatological disorders such as keloids, burns and post-zoster pruritus may also be classified under pruritus in neurological diseases (88–91). Analogously, pruritus in several systemic diseases associated with small fibre neuropathy is similarly included, the list being led by diabetes (92).

4.1.8. Pruritus in psychiatric diseases. It is estimated that at least 32% of psychiatric patients on a psychiatric ward report itch (93). A large population survey showed that adults with depression are twice as likely to experience itch (94) and that the severity of itch increases with symptoms of depression among adolescents (95). The pathophysiological background seems to correlate with production and interaction of neuropeptides such as serotonin (96). Individuals with anxiety tend to itch over time and this has implications for the therapeutic approach (97). Symptoms of obsessive compulsive disorder can manifest with CP, as seen in patients with skin picking (98, 99). "Scalp itch" is often a symptom of depression or a precursor to psychosis. CP can be a symptom in psychotic patients, manifesting as delusional parasitosis, a rare condition that is challenging to treat both for dermatologists and for psychiatrists (100). Overall, the psychiatric population is little studied with regard to skin symptoms, but it is now established that psychiatric morbidity contributes to the pathophysiology of CP in the absence of skin disease (101).

4.1.9. Drug-induced chronic pruritus. Drug-induced pruritus without visible skin lesions accounts for approximately 5% of adverse cutaneous reactions. Almost any drug may induce pruritus by various pathomechanisms (**Table II**) (102). Some may cause urticarial or morbilliform rashes presenting with acute pruritus. Furthermore, drug-induced hepatotoxicity or cholestasis, as well as drugs that cause xerosis, photoallergy or phototoxicity may produce CP on normal skin (103). Increased release of pruritogens (histamine, serotonin, neuropeptides), neurological alterations and neuronal deposition in the skin have also been suggested, but the pathogenesis of drug-induced itch is not fully understood (104). Hydroxyethyl starch (HES), a compound used for fluid restoration, can induce generalised or localised CP in 12–42% of treated patients (105). Duration depends on the cumulative dose, usually persisting for an average of 15 months (after HES deposits in the tissues have been metabolised). In approximately two-thirds of HES-induced pruritus it is generalised and presents without any skin lesions (1, 102).

4.2. Specific patient populations

4.2.1. Chronic pruritus in the elderly. Only a small number of studies have investigated pruritus in the elderly. They are characterised by selection bias and differing endpoints (pruritic skin disease or itch). An American study of cutaneous complaints in the elderly identified pruritus as the most frequent, accounting for 29% of all complaints (106). A Turkish study in 4,099 elderly patients found that pruritus was the most common skin symptom, affecting 11.5% of patients. Women were more frequently affected (12.0%) than men (11.2%). Patients older than 85 years showed the highest prevalence (19.5%) and pruritus was present more frequently

in winter months (12.8%) (107). In a Thai study, pruritic diseases were the most common skin complaint (41%) among the elderly, while xerosis was identified as the most frequent ailment (38.9%) in a total of 149 elderly patients (108). The exact mechanisms of CP in the elderly are unknown. Pathophysiological changes of the aged skin, decreased function of the stratum corneum, xerosis cutis, co-morbidities and polypharmacy may all contribute to its aetiology (109).

4.2.2. Chronic pruritus in pregnancy. There are no epidemiological studies assessing the prevalence of CP in pregnancy. Pruritus is the leading dermatological symptom in pregnancy, estimated to occur in about 18% of pregnancies (110). It can present as specific dermatoses of pregnancy [polymorphic eruption of pregnancy (PEP), pemphigoid gestationis (PG), intrahepatic cholestasis of pregnancy (ICP), atopic eruption of pregnancy (AEP)], but may also occur in other dermatoses coinciding by chance with pregnancy or in pre-existing dermatoses (110–113). Indeed, one of every 5 consultations for pruritus in pregnancy is not related to the specific dermatosis of pregnancy (114).

PEP is one of the most common gestational dermatoses, affecting around one in 160 pregnancies. While PG, PEP and ICP characteristically present in late pregnancy, AEP starts before the third trimester in 75% of cases (1, 111). ICP is characterised by severe pruritus without any primary skin lesions; however, secondary skin lesions occur due to scratching. It is more prevalent among native Indians in Chile (27.6%) and Bolivia (13.8%) depending on ethnic predisposition and dietary factors (115, 116). ICP has decreased in both countries, e.g. to 14% in Chile. ICP is more common in women of advanced maternal age, multiple gestations, a personal history of cholestasis on oral contraceptives and during winter

Table II. Drugs that may induce or maintain chronic pruritus (without a rash)

Class of drug	Substance (examples)
ACE inhibitors	Captopril, enalapril, lisinopril
Anti-arrhythmic agents	Amiodarone, disopyramide, flecainide
Antibiotics	Amoxicillin, ampicillin, cefotaxime, ceftriaxone, chloramphenicol, ciprofloxacin, clarithromycin, clindamycin, cotrimoxazole, erythromycin, gentamycin, metronidazole, minocycline, ofloxacin, penicillin, tetracycline
Antidepressants	Amitriptyline, citalopram, clomipramin, desipramine, doxepin, fluoxetine, fluvoxamine, imipramine, lithium, maprotiline, mirtazapine, nortriptyline, paroxetine, sertraline
Antidiabetic drugs	Glimepiride, metformin, tolbutamide
Antihypertensive drugs	Clonidine, doxazosin, hydralazine, methyl dopa, minoxidil, prazosin, reserpine
Anticonvulsants	Carbamazepine, clonazepam, gabapentin, lamotrigine, phenobarbital, phenytoin, topiramate, valproic acid
Anti-inflammatory drugs	Acetylsalicylic acid, celecoxib, diclofenac, ibuprofen, indometacin, ketoprofen, naproxen, piroxicam
Angiotensin II antagonists	Irbesartan, telmisartan, valsartan
Betablockers	Acebutolol, atenolol, bisoprolol, metoprolol, nadolol, pindolol, propranolol
Bronchodilators, mucolytic agents, respiratory stimulans	Aminophylline, doxapram, ipratropium bromide, salmeterol, terbutaline
Calcium antagonists	Amlodipine, diltiazem, felodipine, isradipine, nifedipine, nimodipine, nisoldipine, verapamil
Diuretics	Amiloride, furosemide, hydrochlorothiazide, spironolactone, triamterene
Hormones	Clomifene, danazol, oral contraceptives, estrogens, progesterone, steroids, testosterone and derivatives, tamoxifen
Immunosuppressive drugs	Cyclophosphamide, cyclosporin, methotrexate, mycophenolatmofetil, tacrolimus, thalidomide
Antilipids	Clofibrate, fenofibrate, fluvastatin, lovastatin, pravastatin, simvastatin
Neuroleptics	For instance, chlorpromazine, haloperidol, risperidone
Plasmaexpanders, blood supplying drugs	Hydroxyethyl starch, pentoxifylline
Tranquilizers	Alprazolam, chlordiazepoxid, lorazepam, oxazepam, prazepam
Uricosstatics	Allopurinol, colchicine, probenecid, tiopronin

months. Scandinavian and Baltic countries are also more affected (1–2%). In Western Europe and North America ICP is observed in 0.4–1% of pregnancies (115–117). PEP is one of the most common gestational dermatoses, affecting about one in 160 pregnancies. While PG, PEP and ICP characteristically present in late pregnancy, AEP starts before the third trimester in 75% of cases (1, 111). ICP is characterised by severe pruritus without any primary skin lesions, but secondary skin lesions occur due to scratching. It is a hormonally triggered, reversible cholestasis occurring in late pregnancy (late second or third trimester) in genetically predisposed women. The prevalence is around 1%, but varies: it is higher in Scandinavia, South America and South Africa (118). The aetiopathogenesis is multifactorial and involves genetic, hormonal and environmental factors such as seasonal variability and dietary factors (119).

4.2.3. Chronic pruritus in children. There are no epidemiological studies assessing the prevalence of CP in children (1, 110). The spectrum of differential diagnosis of CP in children is wide (110, 120), but is dominated by skin diseases, in particular AD. The cumulative prevalence of AD is between 5% and 22% in developed countries. The German Atopic Dermatitis Intervention Study (GADIS) showed a significant correlation between the intensity and severity of pruritus in AD and sleeplessness (121, 122). Chronic spontaneous urticaria (CSU) is a source of pruritus in approximately 3% of children (123), for which a complete characterization of the disease is needed.

A Norwegian cross-sectional questionnaire-based population study in adolescents revealed a pruritus prevalence of 8.8%. Pruritus was associated with mental distress, gender, sociodemographic factors, asthma, rhinoconjunctivitis and eczema (95). Itching of mild to moderate severity may occur in acne (124, 125).

If children are aged > 6 years, the visual analogue scale (VAS), numerical rating scale (NRS) or verbal rating scale can be employed (126). In order to accurately assess the impact of CP in a child's life, some recommended scales include Skindex-16, Skindex-Teen, infant's dermatology life quality index (127), children's dermatology life quality index (128) and ItchyQoL (129). Instruments that measure the effect of the families' quality of life include the dermatitis family impact questionnaire (130). The course of advanced learning for the management of itch (CALM-IT) task force recommend a multidisciplinary and multidimensional approach for children CP (120).

It must be assumed that systemic causes of CP in children are mostly based on genetic diseases or systemic diseases, e.g. biliary atresia or hypoplasia, familial hyperbilirubinemia syndromes, polycystic kidney disease or CKD (1, 131). Drug-induced pruritus without any specific skin symptoms appears to be rare in children (1).

Common medications associated with CP in adults play a minor role in children due to limited use at that age.

5. DIAGNOSTIC MANAGEMENT

5.1. Patient history and clinical examination

Patient history and clinical examination are key to clarifying the aetiology of pruritus, which in turn allows adequate treatment. A number of typical features in the patient history may be helpful and sometimes even diagnostic to identifying the cause of pruritus, e.g. duration, localisation, time course of pruritus and trigger factors, as well as a detailed personal and family history. To obtain this information from the patient, it is helpful to go through their history with a patient history-based algorithm (**Fig. 1**). The following questions can help to compile a patient history:

- Duration and onset of itch (“When did itch start?”) enables a differentiation between acute and CP (more or less than 6 weeks) (9).
- Localisation of pruritus (“Where does it itch?”) makes it possible to distinguish localised pruritus from generalized pruritus.

Localized pruritus is usually caused by itchy dermatosis, when it occurs at localisations where inflamed skin is already present. Localised itch on primarily non-inflamed skin is suggestive for neurological disease, especially when itch appears in an asymmetrical pattern (12, 92, 132–134): unilateral localized pruritus on the back is typical for *notalgia paraesthetica*, whereas itch on lateral aspects of the arms (especially the forearms) is characteristic for *brachioradial pruritus*. Both diseases have a neuropathic origin (81, 135, 136). Pruritus may occur in internal diseases, where it can occur in typical localisations, e.g. on the back and legs in CKD-associated pruritus (42, 137) and on the palms and soles in cholestatic pruritus. Localised vulvar pruritus can be a symptom of iron deficiency (138).

Generalised pruritus can be caused by itchy dermatosis even if the inflamed skin does not show generalised spread, e.g. in patients with psoriasis (139). However, generalised pruritus on primarily normal skin is highly suggestive for not only internal but also neuropathic or psychiatric diseases (140) or use of a drug that causes CP. Interestingly, in one study, whole-body pruritus was found more frequently in patients with dermatosis than in pruritus due to systemic disease (73).

- Intermittent pruritus can be distinguished from constant itch by asking “When does it itch?”. Intermittent pruritus can be a symptom of spontaneous urticaria. In patients with factitial urticaria, pruritus occurs intermittently, typically starting as localised itch and generalising with scratching. Constant pruritus is typical for internal diseases, e.g. renal or liver diseases or pruritus in patients with malignant lymphoma.




Fig. 1. Diagnostic algorithm.

- The time course of pruritus (“When is itch at its maximum/minimum?”) can be indicative for a number of diseases: nocturnal generalised pruritus in association with chills, fatigue and B symptoms (weight loss, fever and nocturnal sweating) is suggestive of malignancy such as Hodgkin’s disease. Seasonal pruritus during wintertime (“winter pruritus”) is found in exsiccation eczema in the elderly.
- Identification of pre-existing skin diseases in the patient history is crucial, especially if pruritus on primarily inflamed skin is assumed. In such cases, a history of AD, psoriasis or lichen planus is suggestive that pruritus has occurred due to an exacerbation of the known disease. An atopic background should always be verified or excluded. It is not uncommon for an atopic disposition to be the only explanation for the onset of pruritus in patients with PUO. However, the most important question to classify pruritus regards skin condition at the time of initial onset of pruritus (“How did the skin look when itch first appeared?”): if pruritus first appeared on primarily diseased (inflamed) skin, pruritic dermatosis – which needs to be diagnosed – is causative. If pruritus appeared on normal looking skin [“pruritus on primarily non-diseased (non-inflamed) skin”], one should consider a systemic, neuropathic or psychiatric disease, drug

- side effects, pregnancy or dermatosis without visible skin changes (9).
- History of pruritus (“How did pruritus or the skin develop over time?”) shows the dynamic of the disease course. Trigger factors and the relationship between pruritus and specific activities can be important: pruritus appearing during physical activity can be caused by AD, cholinergic pruritus and cholinergic urticaria. Pruritus provoked by skin cooling after emerging from a warm shower/bath can be a sign of aquagenic pruritus, polycythaemia vera or xerosis cutis.
- Intensity and quality of itch (burning, painful, stinging, prickling) are best quantified with special tools that have been developed for the assessment of pruritus. For intensity, validated categorical or continuous monodimensional scales, such as the NRS or VAS, are most commonly used. The quality of pruritus is assessed in a descriptive way by use of itch questionnaires. A validated questionnaire for quality of life assessment is the ItchyQol (141).
- Knowledge of pre-existing internal diseases is of importance when pruritus on primarily non-inflamed skin is assumed. In a patient with chronic renal failure or cholestatic liver disease, the primary disease will initially be suspected to cause itch. Unfortunately, there are no defined laboratory cut-off values (e.g.

blood creatinine levels) that are indicative for the causative role of an internal disease.

- A complete history includes documentation of medication use and change of medication in the preceding 12 months prior to the onset of pruritus. Drugs that typically provoke pruritus include opioids, retinoids, antibiotics and new drugs for cancer therapy, especially epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) inhibitors, as well as tyrosine kinase inhibitors. In patients with a history of previous surgery and infusion treatments, hydroxyethyl starch (HES) should be considered as a possible cause.
- Family history is indicative of familial skin diseases or internal disorders that are accompanied by itch. Finally, the personal environment may be instructive: if multiple family members are affected by new-onset of pruritus, scabies or other parasites should be considered.

Clinical examination of the patient should always include a thorough inspection of the entire skin including scalp, nails, oral cavity and anogenital region. While examining skin lesions, the distinction between primary and secondary skin lesions is of the utmost importance, since this allows a distinction between the 3 clinical presentations of pruritus as proposed by the IFSI classification (9).

If primary skin lesions such as macules/erythema, vesicles, papulo-vesicles, blisters, pustules or wheals are observable and, according to the patient history, have been present since the onset of itch, pruritus on primarily diseased (inflamed) skin can be diagnosed. Further investigations can be performed to determine the underlying dermatosis, including skin biopsy, microbiological investigations and, in certain cases, laboratory testing (e.g. IgE, indirect immunofluorescence).

Secondary skin lesions encompass excoriations, ulcerations, necrosis, crusts, papules, nodules, lichenification, atrophy and scars, as well as hyper- and hypo-pigmentation of the skin. In patients with CP these lesions are most likely caused by scratching. If a patient with CP reports that no skin lesions were visible at onset, pruritus on primarily non-diseased (non-inflamed) skin can be diagnosed. An internal disease, medications, pregnancy or specific skin diseases could be causative. Laboratory and radiological investigations, adapted to the patient history and pre-existing diseases, are mandatory to obtain a final diagnosis.

If a patient presents with extensive scratch lesions with a duration of many months or years (e.g. CPG, CPGN), pruritus with chronic secondary scratch lesions is diagnosed. The underlying cause may be a systemic, neurological, psychiatric or dermatological disease. Skin biopsy, laboratory and radiological investigations, as well as procedures suited to the patient's history and pre-existing diseases will yield a final diagnosis.

In addition to examining the entire integument, a general physical examination should be performed in all patients with unclear pruritus, including palpation of abdominal organs and lymph nodes, and a rectal examination.

Expert recommendation: We recommend taking a detailed history of any patient with chronic pruritus. This should include general characteristics of pruritus (e.g. duration, time course, localisation, intensity and quality), knowledge of the personal history, including precise information on medication and family history. We recommend a complete dermatological examination.

5.2. Diagnostic algorithm and diagnostics

Laboratory screening, clinical and technical approaches and investigations are summarised in **Tables III** and **IV**. All this helps to follow a diagnostic algorithm (Fig. 1).

6. THERAPY

6.1. Therapy: general principles including emollients

It is important to establish an individual antipruritic therapy regimen that takes into account the age of the patient, pre-existing diseases, medications as well as the quality and intensity of CP. Elderly patients, pregnant women and children need special attention (see Sections 6.6.1, 6.6.2 and 6.6.3). As the care of patients with CP often extends over a long period, with initial uncertainty

Table III. Diagnostics: laboratory screening, diverse approaches and investigations

Chronic pruritus: first-step lab screening	<ul style="list-style-type: none"> • Differential blood cell count, erythrocyte sedimentation rate (ESR) • Creatinine, urea • Transaminases (ASAT,ALAT), alkaline phosphatase, gamma-glutamyltransferase (γ-GT) • Lactate dehydrogenase (LDH) • TSH • Glucose • Ferritin, C-reactive protein (CRP) • Age > 40 y: stool occult blood
Chronic pruritus: further investigations	<ul style="list-style-type: none"> • Immunoelectrophoresis • Hepatitis serology, cholesterol, triglycerides • Calcium, parathormone • Biopsy with DIF (mastocytosis, pemphigoid, etc.) • Swab for candida (mucocutaneous pruritus) • Urine: mast cell metabolites • Further imaging studies and bone marrow investigation for mastocytosis
Chronic pruritus: approach I	<ul style="list-style-type: none"> • Detailed history: preceding skin changes? • Weight loss, fever, night sweats, fatigue? • Emotional stress? • Medication? Drug abuse? • Physical examination • Subtle primary skin disorders: xerosis, scabies • Bath oil, emollient/education • Follow-up appointment after 2 weeks
Chronic pruritus: approach II	<ul style="list-style-type: none"> • Detailed history renewed • Lab screening (see above) • Detailed general physical examination: LN, rectal • Stool for parasites • Chest X-ray • Biopsy • Complete internist work-up, further imaging • Follow-up

Table IV. Laboratory and technical investigations in chronic pruritus (CP) due to systemic diseases

Laboratory and technical screening-basic	Complete blood count, creatinine, urea, ASAT, ALAT, alkaline phosphatase, γ -GT, TSH, glucose, chest X-ray, (stool test for parasites in genito-anal pruritus)
Metabolic and endocrine diseases	
Renal insufficiency	Lab I: Creatinine (and urea for elderly) Lab II: Calcium, phosphate, parathormone, HCO ₃ , urinalysis with urine protein concentration. ANA, anti-ds-DNA-Ab, ANCA, anti-GBM-Ab, etc. Tech: Sonography of the kidneys, CT or MRI
Liver diseases with or without cholestasis	Lab I: ALAT, ASAT, γ -GT, alkaline phosphatase, HBV-, HCV-serology Lab II: Bilirubin, LDH, antimitochondrial antibodies (AMA), anti-smooth muscle Ab (SMA), antiactin Ab, ANA, ANCA Tech: sonography of the liver, CT or MRT, [magnetic resonance cholangiogram (MRC) or endoscopic retrograde cholangiogram (ERC) to rule out primary sclerosing cholangitis]
Hyperparathyroidism	Lab II: Only serum-calcium is elevated Calcium, parathormone phosphate, vitamin D (1,25-Vit D, 25-Vit D) Tech: sonography of the parathyroid glands, scintigraphy, MRI
Hyper- and hypothyroidism	Lab I: TSH Lab II: fT ₃ , fT ₄ , thyroid peroxidase antibody; thyroglobulin antibody; thyroid stimulating hormone receptor antibody.Tech: Sonography of thyroid gland
Anaemia	Lab I: Complete blood count including MCV and MCHC, LDH, ferritin Lab II: Reticulocytes, haptoglobin, vitamin B12, folic acid.
Iron deficiency	Lab II: Bone marrow aspiration Lab I: Ferritin
Malabsorption	Lab II: Serum iron, transferrin, transferrin saturation (TSAT). stool occult blood Lab tests only in case of typical history (known pancreatic disease, history of intestinal surgery) or symptoms such as chronic diarrhoea or steatorrhoea and weight loss. Lab II: Serum protein and serum albumin, gliadin antibody Vitamin A (hyperkeratosis due to vitamin A deficiency), vitamin B12 (neuropathy due to vitamin B deficiency) Tech: endoscopy with biopsy
Other diseases	
Pruritus of the elderly	Lab I: Differential blood count, creatinine, urea, estimated glomerular filtration rate (eGFR), ALAT, ASAT, alkaline phosphatase, TSH
Infectious diseases	In the case of clinical suspicion due to history: HIV antibodies, In the case of clinical suspicion due to history and/or when eosinophilia was found in differentiated blood count: Stool culture and microscopic examination for parasites
Haematological disorders	<u>Polycythemia vera</u> Lab I: Blood count (elevated haematocrit and haemoglobin, increase of red blood cells, leukocytosis, thrombocytosis), ESR Lab II: To rule out secondary erythrocytosis: erythropoietin (EPO), JAK2 V617F Lab III: Bone marrow Tech: Abdominal sonography, CT or MRI <u>Lymphoma</u> Lab I: Blood count, ESR Lab II: Bone marrow, flow cytometry Tech: Sonography, thoracoabdominal CT or MRI
Neurological diseases	In the case of suspected neurological disorder: Lumbar puncture and MRI <u>Multiple sclerosis</u> Lab: Cerebrospinal fluid analysis (oligoclonal bands?) Tech: MRI (CT) of brain <u>Brain tumours</u> Lab: Cerebrospinal fluid analysis with histopathology Tech: MRI (CT) of brain <u>Notalgia paraesthetica</u> MRI of thoracic spine <u>Brachioradial pruritus</u> MRI of thoracic and cervical spine
Psychiatric or psychosomatic diseases	Psychiatric assessment, with short questionnaire for depressive and anxiety disorders
Pregnancy with or without cholestasis	Lab I: ASAT, ALAT, AP, γ -GT Lab II: Bile acids, bilirubin, serology for HAV, HBV, HCV, EBV and CMV, autoimmune screen for chronic active hepatitis and primary biliary cirrhosis (anti-smooth muscle and antimitochondrial antibodies) (113) Tech: liver ultrasound
Drug induced pruritus	Lab I: γ -GT, AP, bilirubin, AST; ALT, LDH. Skin biopsy in the case of HES exposure (electron microscopy)

about the origin of the pruritus, frustration regarding the failure of past therapies and general psychological stress frequently occurs. Taking a careful history on the occurrence and characteristics of pruritus is very important (see Section 5.1). The diagnostic procedures and therapy should be discussed with the patient in order to achieve the best possible concordance and compliance.

As a first step, the patient should be informed about general pruritus-relieving measures (Table V). These include simple and helpful tips such as keeping room temperatures low and applying moisturisers to improve skin barrier and reduce itching. Although many patients

report that cold showers reduce itch, no scientific studies have been performed to confirm this observation. On the other hand, brief hot showers have shown itch-relieving effects in experimental studies applying heat to chronic pruritus and atopic skin (142, 143). Also, lukewarm baths with colloidal oatmeal may restore skin barrier and soothe pruritus (144). Moisturisers with water and liquid paraffin base are used in soothing creams and emulsions. Several active ingredients are used in emollients suitable for dry skin. The effects of urea (5–10%) and glycerol (20%) on pruritus are the best studied (145, 146). Propylene glycol (20%) and lactic acid (1.5–5%) may also

Table V. General measures for treating chronic pruritus (CP)

Application of
Soft clothing permeable to air, e.g. cotton. Dress in layers to avoid sweating
Low room temperature at night
Mild, non-alkaline, perfume-free soaps, moisturizing syndets and shower/bath oils
Skin moisturizer on a daily basis, especially after showering and bathing.
Emollients, especially at night: creams/lotions/gels with, e.g. urea (5–10%), glycerol (20%), camphor (2%), menthol (1%), zinc (10%), pramoxine (1%), polidocanol (2–10%)
Luke-warm water, bath (max 20 min), possibly adding oatmeal or potassium permanganate, dabbing the skin dry after bathing
Cooling wet or fat-moist wraps
Avoidance of
Factors that can contribute to dry skin, such as dry climate, sauna, alcoholic compresses, frequent washing and bathing
Excitement, strain, negative stress
Very hot and spicy foods, large amounts of hot drinks and alcohol
Contact with allergenic and irritant substances (e.g. fragrances, preservatives and surfactants)
Relaxation techniques
Autogenic training, relaxation therapy, psychosocial education
Education
Educational training programs for coping with the vicious itch-scratch-itch cycle (121, 122, 478)

contribute to hydration of the skin and to a reduction in pruritus (147). In addition, propylene glycol and lactic acid have antimicrobial properties, making preservatives redundant. Another antipruritic agent with antimicrobial properties is potassium permanganate, which can be used as an active ingredient in baths.

Emollients containing N-palmitoylethanolamine (PEA) (0.3%), an endogenous lipid, have been shown to significantly improve skin barrier function (148) and weak to moderate antipruritic and analgesic effects in experimentally induced pain, pruritus and erythema by topical application (149, 150). In (non-vehicle controlled) clinical trials and case series, it proved to have antipruritic effects in CPG, AD, CKD-associated pruritus and PUO (151–153), as well as analgesic effects in postherpetic neuralgia (154). In a monocentric, double-blind RCT of 60 patients with AD it was shown that the preservation and loss of moisture (measured by transepidermal water loss) were greatly improved with a PEA containing cream compared to the vehicle (148); however, a vehicle-controlled study with 100 subjects did not show any significant difference between the lotion with and without PEA (155). Thus a PEA-containing topical can be considered an emollient therapy. Allergenic compounds (e.g. fragrances or preservatives) and irritant substances (e.g. surfactants) in emollients should be avoided.

Prior to further symptomatic therapy, the patient should undergo a careful diagnostic evaluation, as well as treatment for any underlying disease (Fig. 1, Tables III and IV). Pharmacologic interventions for specific pruritic diseases, e. g. AD and urticaria, should be performed according to the current guideline of the specific disease and the field's Cochrane Group (6, 7, 156–161).

If pruritus continues to persist, consecutive or combined step-by-step symptomatic treatment is necessary (**Table VI**). Before considering systemic treatment, patient adherence to topical treatment, including skin care, needs to be ensured (162). Severe generalised CP often requires multiple treatment approaches, which may be administered alone or in different combinations and sometimes repeated. Some therapies are not approved for CP and can only be prescribed “off-label”, which requires separate informed consent.

Expert recommendation: We recommend the use of moisturisers and emollients depending on the status of the skin.

6.2. Causative therapy and aetiology-specific treatment

CP can be addressed by treating the underlying disease, e.g. specific treatments for underlying dermatoses, avoidance of contact allergens, discontinuation of implicated drugs, specific internal, neurological and psychiatric

Table VI. Stepwise symptomatic-therapeutic approach in chronic pruritus (> 6 weeks)

	Therapy
Step 1	<ul style="list-style-type: none"> • General therapeutic measures (Table V), especially basic therapy with moisturisers • Initial symptomatic therapy: systemic H1 antihistaminics*, topical corticosteroids
Step 2	<ul style="list-style-type: none"> • Symptomatic causative-adapted therapy (Tables VII–X) if origin is unknown
Step 3	<ul style="list-style-type: none"> • In pruritus of unknown origin or therapy refractory cases in step 2: • symptomatic topical therapy, especially in localised forms with, e. g. calcineurin inhibitors, cannabinoid agonists, capsaicin • and/or systemic therapy with gabapentin or pregabalin, antidepressants (doxepin, mirtazapine, paroxetine), UV phototherapy, naltrexone, immunosuppressants (cyclosporine)
Concomitant treatment in every step	<ul style="list-style-type: none"> • Diagnostics and treatment of underlying disease • General therapeutic measures (Table V) • In sleep disorders: sedative H1-antihistaminics, tranquilisers, tricyclic antidepressants or neuroleptics • Psychosomatic care, behavioural therapy for scratch behaviour • In erosive scratch lesions: topical antiseptics, topical corticosteroids

*There is no evidence for the following diagnoses: cholestatic pruritus, nephrogenic pruritus.

Table VII. Therapeutic options in chronic kidney disease-associated pruritus

Antipruritic effects in controlled studies
<ul style="list-style-type: none"> Activated charcoal 6g/day (61) Gabapentin 300 mg 3x/week postdialysis (290), pregabalin 50 mg/every other day (304) Gamma-linolenic acid cream 3x/day (487) Capsaicin 3–5x/day (188, 189) UVB phototherapy (488) Acupuncture at the Quchi (LI11) acupoint (411) Nalfurafine intravenously postdialysis (36) Thalidomide 100 mg/day (356) Montelukast 10 mg/day (489)
Equivocal effects in controlled studies
<ul style="list-style-type: none"> Naltrexone 50 mg/day (37, 38) Ondansetron 8 mg orally or i.v. (346, 347)
Antipruritic effects in case reports
<ul style="list-style-type: none"> Cholestyramine (61) Tacrolimus ointment 2x/day (221, 222) Cream containing structured physiological lipids with endocannabinoids (152) Mirtazapine (329) Cromolyn sodium (490) Erythropoietin 36 IU/kg body weight 3x/week (491) Lidocaine 200 mg i.v./day (61) Ketotifen 1–2 mg/day (492)

therapies, surgical treatment of an underlying tumour or transplantation of organs. Normally, there is sudden relief of pruritus when the underlying disease improves, e.g. when Hodgkin's disease responds to chemotherapy or when a patient with PBC has received a transplant. For some underlying diseases, specific treatments have proven to be successful in relieving pruritus, even if the underlying disease is not treated. Aetiology-specific treatments act on a known or hypothetically assumed pathogenesis of pruritus in underlying diseases. Evidence of efficacy can be found in controlled studies for only a few of these treatments. Treatments for CP in specific diseases are presented in **Tables VII–XI**. When deciding the choice of treatment, consideration should be given to the level of evidence, side-effects, practicability, costs, availability of a treatment and individual factors such as patient age.

Table VIII. Therapeutic options in hepatic and cholestatic pruritus

Antipruritic effects in controlled studies
<ul style="list-style-type: none"> Cholestyramine 4–16 g/day (not in primarily biliary cirrhosis!) (46) Ursodesoxycholic acid 13–15 mg/kg/day (493, 494) Rifampicin 300–600 mg/day (495); (49) Naltrexone 50 mg/day (277, 496) Naloxone 0.2 µg/kg KG/min (274) Nalmefene 20 mg 2x/day (275) Sertraline 75–100 mg/day (322) Thalidomide 100 mg/day (497)
Equivocal effects in controlled studies
<ul style="list-style-type: none"> Ondansetron 4 mg or 8 mg i.v. or 8 mg orally (333, 339, 340) In PBC: bezafibrate 400 mg/day in combination with ursodesoxycholic acid (498, 499)
Antipruritic effects in case reports
<ul style="list-style-type: none"> PBC: Nalfurafine (500) Phenobarbital 2–5 mg/kg KG/day (501) Stanozolol 5 mg/day (502) Paroxetine (503) Phototherapy: UVA, UVB (504) Bright light therapy (10,000 Lux) reflected toward the eyes up to 60 min twice/day (505) Etanercept 25 mg sc. 2x/week (506) Nasobiliary drainage (507) Plasma perfusion (504) Extracorporeal albumin dialysis with Molecular Adsorbent Recirculating System (MARS) (508–513) Liver transplantation (514)

Table IX. Antipruritic therapy of atopic dermatitis (AD) (5) and (160, 161)

Antipruritic effects confirmed in controlled studies
<ul style="list-style-type: none"> Glucocorticosteroids (topical and oral) Cyclosporin A Mycophenolate mofetil (MMF 2 g/day or EC-MPS 1440 mg/day) Dupilimab (515) (300 mg/weekly or/2 weeks) Tacrolimus ointment (2x/day) Pimecrolimus cream (2x/day) Proactive therapy with steroids and tacrolimus ointments (2x/week) Naltrexone 50 mg/day (283, 516)
Equivocal results
<ul style="list-style-type: none"> Antihistamines (topical and systemic) Allergen-specific immunotherapy (ASIT) Azathioprine (2–5 mg/kg/day, starting dose 50 mg/day) Methotrexate (5–25 mg 1x/week) Apremilast (20–30 mg 2x/day; dosage from BNF) Interferon gamma, i.c.
Antipruritic effects shown in case reports
<ul style="list-style-type: none"> Intravenous immunoglobulins (IVIG) UVA1-/UVB 311 nm/PUVA therapy Leukotriene antagonists (e.g. zafirlukast/montelukast) Capsaicin (3–5x/day) Immunoabsorption Anti-TNFα therapy (infliximab 10 mg/kg for 7 cycles) Omalizumab (150 mg for 10 cycles) Combination omalizumab with IVIG or rituximab

Table X. Therapeutic options in polycythaemia vera

Effects shown in case reports
<ul style="list-style-type: none"> Paroxetine 20 mg/day (63, 316) Hydroxyzine (63) Fluoxetine 10 mg/day (316) Aspirin (517) Cimetidine 900 mg/day (518, 519) Pizotifen 0.5 mg 3x/day (520) Cholestyramine (521) Ultraviolet B phototherapy (445) Photochemotherapy (PUVA) (522, 523) Transcutaneous electrical nerve stimulation (524) Interferon-alpha (525–528)

Table XI. Therapeutic options in aquagenic pruritus

Effects confirmed in case reports (529–531)
<ul style="list-style-type: none"> Topical capsaicin 0.025–1% thrice/day for 4 weeks Glycerol trinitrate topically 2% Transdermal application of scopolamin, topically 3% or 9% Baths with sodium bicarbonate (0.5–1 kg/bath) Bath and systemic PUVA, UVB, UVA + NB-UVB (447, 449–451, 532) Propranolol 10 to 80 mg/day (533) Atenolol 25 mg/day (534) Clonidine 0.1 mg twice/day Astemizol 10 mg/day Ibuprofen (prior to bathing) Pregabalin 150–300 mg/day Antihistamines, e. g. hydroxyzine 25 mg/day, chlorpheniramin 8 mg/day, cetirizine, loratadine, fexofenadine, terfenadine H2-blockers: cimetidine 900 mg/day Opioid receptor antagonists, e. g. naltrexone 25–50 mg/day (535) Selective serotonin reuptake inhibitors, e. g. paroxetine 20 mg/day, fluoxetine 10 mg/day Interferon-alpha 2b 5x 3 mil IE 1st week, 3x3 mil IE 2nd–4th week
Effects confirmed in RCT
<ul style="list-style-type: none"> Acetylic salicylic acid 300–500 mg/day

6.3. Topical therapy

6.3.1. Local anaesthetics. Local anaesthetics (LA) are a heterogeneous group of compounds, e.g. benzocaine, lidocaine and polidocanol. They act via different groups of skin receptors, interfering with peripheral neural transmission of pruritus. Topical LA are widely used for the symptomatic treatment of localised forms of CP,

such as neuropathic pruritus, CKD-associated pruritus, post-burn pruritus and paraneoplastic pruritus, as well as in the palliative care setting (163).

In experimental studies, LA exhibited only limited antipruritic effects in both histamine- and cowhage-induced pruritus, with short-term duration (10 min) after topical application (164, 165). Successful use in the treatment of localised forms of pruritus such as notalgia paraesthetica has been reported in case series (166, 167).

Polidocanol, an anionic surfactant with local anaesthetic properties, selectively reduces cowhage-induced pruritus via PAR-2 inhibition (168). It is commonly used in different galenic formulations, alone (polidocanol 2–10%) or in combination with other active substances (urea) to treat larger skin areas, i.e. atopic skin.

Topical 1% pramoxine hydrochloride has been shown to ameliorate CKD-associated pruritus in a double-blind, placebo-controlled study and can be used to treat larger skin areas, also in combination with other antipruritic compounds (lactic acid, hydrocortisone) (169).

Ethyl chloride spray, a topical cooling and anaesthetic agent, reportedly reduces histamine-induced itch in experimental studies and finds limited application in localised pruritus secondary to allergy skin testing (170). *Expert recommendation:* We suggest the application of topical anaesthetics for localised pruritus including polidocanol for selected cases of generalised pruritus.

6.3.2. Zinc, menthol and camphor. Although zinc oxide has been used in dermatology for over 100 years due to its anti-inflammatory, antiseptic and antipruritic properties and its safety, there is only scarce literature on its effects. Prescriptions of zinc are frequent, with concentrations varying from 10–50% in creams, liniments, lotions, ointments and pastes that are useful in the treatment of pruritus, especially localised forms of pruritus, in children as well as in adults (171). Calamine, which is often found in cooling liniments, contains 98% zinc oxide (171). In an experimental study zinc oxide was shown to be as effective as moderate potency corticosteroid in suppressing contact dermatitis (172).

Menthol is an alcohol obtained from mint oils, or prepared synthetically. Applied to the skin and mucous membranes, it causes a sensation of coldness, followed by an analgesic effect (171). Menthol is used in dusting powders, liniments, lotions and ointments in concentrations from 1% to 10% (171). It has been shown to have a cooling effect for up to 70 min and to act as a counter-irritant (173). Menthol binds to the TRPM8 receptor (174), which belongs to the same TRP family of excitatory ion channels as TRPV1, the capsaicin receptor. These two receptors have been shown to occasionally co-exist in the same primary afferent neurons and promote thermo-sensations at a wide range of temperatures, 8–28°C and >42°C, respectively (174). First studies showed that topicals containing the TRPM8 agonist combination or menthoxypropanediol ameliorate CP (175, 176).

Camphor, an essential oil-containing terpene, is soluble in alcohol (171). Applied to the skin, it causes a sensation of warmth followed by a mild degree of anaesthesia (171). Camphor has been used in dermatology for decades in liniments, lotions and ointments at concentrations ranging from 2% to 20%. It has been shown to specifically activate another constituent of the TRP ion channel family, namely TRPV3 (177). Camphor was recently demonstrated to activate the capsaicin receptor, TRPV1, while menthol also activates the camphor receptor, TRPV3. These findings illustrate the complexity of sensory perception and explain the efficacy of ointments containing both menthol and camphor (171).

Expert recommendation: We recommend topical application of menthol and its derivatives. We suggest topical application of camphor or zinc.

6.3.3. Capsaicin. Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is the pungent agent of chilli peppers and is used as a pain-relieving medication (178). Topical application of capsaicin activates sensory C-fibres to release neurotransmitters that induce dose-dependent erythema and burning. After repeated applications of capsaicin, the burning fades due to tachyphylaxis and retraction of epidermal nerve fibres (178). However, pruritus recurs some weeks following discontinuation of therapy, indicating no permanent degeneration of the nerve fibres (179).

The greater the initial dose of capsaicin and the more frequent the applications, the sooner desensitization will appear and pruritus will disappear. The burning sensation accompanying topical treatment may be reduced by lidocaine or cooling of the skin (180–182). Unusual adverse effects include cough or sneezing due to inhalation of capsaicin from the skin or from the jar, as well as its effect on sensory nerve fibres in the mucous membranes (178). A lower concentration of capsaicin and less frequent applications will induce tachyphylaxis later, but may ensure better compliance. The concentration of capsaicin varies in different studies, but 0.025% capsaicin is well tolerated by most patients. If capsaicin is not available in this concentration as a standard drug, it can be produced using a lipophilic vehicle. Capsaicin is also readily soluble in alcohol (0.025% capsaicin in spir dil) suitable to treat burning scalp. A weaker concentration of 0.006% capsaicin is recommended for intertriginous skin, e.g. pruritus ani (183). High dose capsaicin treatment (8% patch) for neuropathic pruritus induced CP relief for up to 12 weeks and longer (184).

Topical capsaicin's effects have been confirmed in controlled clinical trials for different pain syndromes and neuropathy, as well as notalgia paraesthetica (185), brachioradial pruritus (83), pruritic psoriasis (186, 187) and haemodialysis-related pruritus (188, 189). Case reports and case series described effects in hydroxyethyl starch-induced pruritus (190, 191), prurigo nodularis (191–194), lichen simplex (191, 193), nummular ec-

zema (191), aquagenic pruritus (195) and psoralen and ultraviolet A (PUVA)-associated pruritus (196). High-concentration topical capsaicin for the treatment of postherpetic neuralgia and HIV neuropathy have been evaluated in a Cochrane review (197).

Expert recommendation: We suggest topical capsaicin for localized forms of CP.

6.3.4. Topical glucocorticosteroids. Topical glucocorticosteroids are the first line therapy for inflammatory dermatoses and the antipruritic effect they display has been attributed to an indirect consequence of their anti-inflammatory properties. Thus they are not currently recommended for the treatment of pruritus in the absence of a skin disease. Once- or twice-daily application of a medium or high potency glucocorticosteroid to the trunk and extremities or a low potency preparation on the face or intertriginous areas for approximately 1–3 weeks is recommended in the case of pruritic dermatoses (198). Prolonged use and application to large areas is to be avoided. Children, pregnant women and elderly patients are especially susceptible to the adverse effects of glucocorticosteroids and should be closely monitored (199, 200).

Some recent data hint at the possibility of an alternative mode of antipruritic action of glucocorticosteroids. Pruritus experimentally induced by histamine was significantly suppressed by topical hydrocortisone when compared to placebo (201). In another experimental model itch relief from nickel allergy provided by methylprednisolone aceponate was very rapid and preceded resolution of all other eczema findings, suggesting a direct antipruritic effect of the agent rather than just an indirect anti-inflammatory one (202).

Some studies suggest that topical corticosteroids such as betamethasone valerate are effective in CNPG (203, 204). Intralesional application in single nodules of CPG may be considered but there are no studies verifying the efficacy of this therapy.

Expert recommendation: We recommend application of topical glucocorticosteroids in CP associated with inflammatory dermatoses and CPG. We recommend against topical glucocorticosteroids in CP on non-inflamed skin. We recommend against long-term treatment with topical glucocorticosteroids.

6.3.5. Tacrolimus and pimecrolimus. The effects of the topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus on pruritus are mediated both through their immunological and their neuronal properties (205). Paradoxically, while they can induce transient pruritus at the beginning of treatment, in the medium-term they may provide an alternative treatment for many causes of pruritus. An initial burning sensation upon application, which may be due to activation of TRPV1, can be a biomarker of antipruritic effect on individual patients with CP (206). TCIs are highly effective against pruritus in AD, and do not have the atrophying effects of topical corticosteroids

on the skin (207, 208). Furthermore, 0.1% tacrolimus ointment is more effective at reducing symptoms of AD when compared with low-potency corticosteroids, 0.03% tacrolimus and 1% pimecrolimus cream (209). Clinical trials have shown benefit of both pimecrolimus and tacrolimus in seborrhoeic dermatitis, genital lichen sclerosis, intertriginous psoriasis and cutaneous lupus erythematosus and – only for tacrolimus – in resistant pruritus ani (210–218). Both substances can be used to treat localised forms of CP such as genital pruritus (219). In other diseases, the available data are limited to small case series, or individual cases, e.g. hand eczema (pimecrolimus), rosacea (tacrolimus), graft-versus-host disease (tacrolimus), vulval pruritus (tacrolimus) or Netherton's syndrome (tacrolimus, pimecrolimus). Topical tacrolimus has been shown anecdotally to be effective in pruritus associated with systemic diseases such as PBC (220) and chronic renal insufficiency (221, 222). Despite early reports of efficacy of tacrolimus on CKD-associated pruritus, these observations have not been confirmed in a controlled study and so it is not recommended in these patients, although it may have some benefit in combination with systemic therapies (e.g. nalfurafine) (223–225).

Numerous clinical trials have demonstrated the safety of using TCIs routinely, in children as well as adults (209, 226). The transient burning upon application diminishes after 5–10 days of regular (e.g. twice-daily) application in most cases (227). Some patients may experience flushing upon taking alcohol; however, this can be blocked with acetylsalicylic acid (500 mg) taken in advance of drinking alcohol (208). Long-term studies are required to assess the risk of lymphoma in both adult and paediatric patients using TCIs; however, this seems to be extremely rare (228). In the elderly population TCIs are recommended for inflammatory skin diseases and, if effective, can be used indefinitely (229).

Expert recommendation: We suggest tacrolimus and pimecrolimus for the treatment of localized forms of CP.

6.3.6. Acetylsalicylic acid. Topical acetylsalicylic acid (acetylsalicylic acid/dichlormethane solution) has been described to have antipruritic effects in occasional patients with lichen simplex and CPG (230, 231). However, this beneficial effect could not be confirmed in experimentally induced itch with histamine (232).

Expert recommendation: We cannot make a recommendation with respect to topical acetylsalicylic acid for the treatment of CP.

6.3.7. Doxepin. The tricyclic antidepressant doxepin showed antipruritic effects when applied as a 5% cream in double-blind studies for treatment of AD (233), lichen simplex, nummular dermatitis and contact dermatitis (234). Topical doxepin therapy is not licensed and not used in any European country except for the UK (Xepin®) (235–237).

6.3.8. *Topical mast cell inhibitors.* Pruritus in AD responds to topical sodium cromoglycate (238), which was confirmed by a placebo-controlled study (239). Comparison with vehicle showed that topical sodium cromoglycate (especially 4%) was effective in histamine-induced itch (240).

Expert recommendation: We suggest against the use of topical mast cell inhibitors for the treatment of CP.

6.4. Systemic therapy

6.4.1. *Antihistamines.* Antihistamines are the most widely used systemic antipruritic drugs in dermatology (241). Drugs that target the H1 receptor can effectively block the acute itch of cutaneous conditions as urticaria or insect bites, among others (242).

First-generation antihistamines, such as chlorpheniramine, clemastine, cyproheptadine, diphenhydramine, hydroxyzine, and promethazine are known to bind not only to H1-receptors, but also to muscarinic, α -adrenergic, dopamine or serotonin receptors and have a central sedative effect. Hydroxyzine is the most commonly used first-generation antihistamine showing sedative, anxiolytic and antipruritic activities. In adult patients it is recommended as an antipruritic agent at a dosage of 25 mg at night, increasing to 25 mg 3 to 4 times a day if necessary. In children under 6 years the effective dose is up to 50 mg/day in divided doses, and 50–100 mg/day in children aged 6–12 years (243). However, the sedative effect of such antihistamines induce impaired sleep, interfering with the REM phase. A prospective cohort study recently suggested that its cumulative long-term use (and other cholinergic drugs) is associated with increased risk of dementia (244). Increased drowsiness may be problematic in the elderly (229). Due to these side effects, the use of sedative antihistamines is nowadays limited, and the dose modified accordingly, especially in vulnerable populations (245).

Second-generation antihistamines such as cetirizine, levocetirizine, loratadine, desloratadine, ebastine, fexofenadine, rupatadine or bilastine have minimal activity on non-histaminic receptors, little sedative effect, and a longer duration of action compared to the first generation (246). For the treatment of PUO, loratadine (10 mg), fexofenadine (180 mg) or cetirizine (10 mg) are helpful. Cetirizine may be preferred for its mild sedative properties (247). Oral cetirizine has been shown to be preferable in CP to narrowband (NB) ultraviolet B (UVB) phototherapy, for reasons of cost-effectiveness and time-saving (248).

In general, the non-sedative H1-receptor antagonists offer an effective reduction of CP in diseases associated with increased mast cell degranulation such as urticaria or mastocytosis (249). Rupatadine, a dual inhibitor of histamine H1 and PAF receptors, has been shown to significantly reduce the severity of pruritus in masto-

cytosis, as well as mosquito bite allergy and urticaria in both adults and children (250). In adult patients with confirmed mosquito-bite allergy, rupatadine 10 mg administered prophylactically has been shown to be effective in reducing subsequent wealing and skin pruritus (251). The newest antihistamine, bilastine, is highly selective for the H1 receptor. With properties of rapid onset, prolonged duration of action, no need for dose adjustment, and low potential for central nervous system (CNS) impairment or drug–drug interaction, bilastine is a front runner among other second-generation antihistamines in the management of chronic urticaria (252). European guidelines on urticaria (6) recommend second-generation anti H1-antihistamines as the first-line therapy for chronic spontaneous urticaria, starting at licensed doses and being increased to up to 4 times the dose if licensed doses fail to control the disease. Systemic H1-antihistamines are often employed to treat pruritus in AD. The older, sedating H1-antihistamines may be more useful for this indication especially in acute AD flares, improving sleep quality in the short term, although these are not recommended for long-term use in children (159). The European guideline on AD does not recommend the general use of any antihistamines for AD, since there is no high-level evidence that non-sedating antihistamines reduce itch in AD, or that sedating antihistamines are of benefit, except for aiding sleep (253, 254).

It is currently thought that pruritus in psoriasis is also not histamine-mediated, and therefore antihistamines are not routinely recommended (242). Recently, however, both sedating and non-sedating antihistamines have been shown to be moderately effective in reducing itch in patients with psoriasis, but further studies are needed on larger patient groups (255).

Antihistamines are widely used as first-line drugs for the treatment of CP associated with various systemic diseases such as chronic renal failure, cholestasis, hematopoietic diseases and thyroid disorders. However, conventional doses of antihistamines in the treatment of pruritus in internal diseases have not proven to be effective (246).

Antihistamines have been shown to be safe in specific populations. However, while there is no particular antihistamine that is universally effective for the treatment of pruritus, certain antihistamines [e.g. loratadine, cetirizine or rupatadine (256)] are thought to be safer for use in children, pregnancy and lactation, and so may be preferred in these patients (206). The use of first-generation antihistamines is to be avoided in pregnant women (257). For the paediatric management of pruritus, long-term use of first-generation antihistamines is not recommended (158, 159). The associated psychomotor impairment may impact the education and safety of children, and remains even while the child becomes used to the sedating effects (258). Second-generation antihistamines with

appropriate dose adjustment are the first-line therapy for chronic urticaria in children (259).

Although identified in human skin, H₂-receptors play a minor role in pruritus, and H₂-receptor antagonists alone have no antipruritic effect (260, 261). A combination of H₂-antihistamines and H₁-antihistamines has been used in the treatment of pruritus in small trials, but the results are conflicting (260, 261). It has recently been found that H₃- and H₄-histamine receptors are involved in pruritus, with the H₄ in particular being associated with mast cell function, as well as T cells, dendritic cells, monocytes and eosinophils (262). The efficacy of an H₄ receptor antagonist is currently under research in clinical studies and may be available as an antipruritic therapy in the near future (263). There is pre-clinical evidence that local antagonism of the H₃ receptor can induce scratching; therefore, new drugs that target the H₃R are anticipated in the field, with the hope that more effective treatment of chronic pruritus can be offered to patients in the future (264).

A case series suggests that up dosing of antihistamines may also be beneficial in CP (265).

Expert recommendation: We recommend treating CP in urticaria with non-sedating H₁-antihistamines. We suggest non-sedating H₁-antihistamines in CP in mastocytosis. We suggest non-sedating and/or sedating H₁-antihistamines as an initial symptomatic therapy of CP.

6.4.2. Mast cell inhibitors. Ketotifen (1 mg twice daily), showed antipruritic effects in patients with CKD-associated pruritus, but less than gabapentin (266). Cromolyn sodium and placebo were compared in 62 haemodialysis patients and a significant decrease in itch was seen in the treatment group, but without effects on tryptase level (267).

Expert recommendation: We suggest against the use of systemic mast cell inhibitors for the treatment of CP.

6.4.3. Glucocorticosteroids. Systemic glucocorticoids (GCs) are commonly used to treat severe CP associated with inflammatory skin disease or systemic disease, supported only by limited clinical evidence. In clinical experience, pruritus ceases within approximately 30 min of i.v. glucocorticosteroids in the treatment of urticaria or drug-induced exanthema. Likewise, in AD, allergic contact dermatitis, dyshidrosis and bullous pemphigoid a rapid reduction in pruritus is observed, which can be explained by their high anti-inflammatory potency. Thus, while systemic glucocorticosteroids should not be considered as an antipruritic for long-term therapy, short-term use is possible in cases of severe pruritus in inflammatory skin diseases; however, they should not be used for a period of more than 2 weeks (268) due to their severe side-effects.

Severe, intractable lymphoma-related paraneoplastic CP can be successfully treated with short courses of systemic GCs (269). An improvement in cutaneous T-cell

lymphoma-related pruritus via suppression of IL-31 production, which has been shown to correlate with pruritus severity, was reported using dexamethasone (270, 271).

Prednisone is the most commonly selected oral corticosteroid, initially at a daily dose ranging from 2.5 mg to 100 mg or more, usually starting at a dose of 30–40 mg daily. In exceptional cases i.v. methylprednisolone is used at a dose of 500 mg–1 g/day, due to its high potency and low sodium-retaining activity. It is important to remember that the dosage should be tapered in accordance with pruritus severity. Before discontinuing systemic therapy, one may change to topical corticosteroid therapy. Corticosteroids should be used with caution in children, the elderly and in patients with relevant metabolic disorders such as diabetes.

Expert recommendation: We suggest systemic glucocorticoids as a short-term treatment in selected cases of refractory CP, especially in paraneoplastic pruritus and palliative care.

6.4.4. Opioid receptor agonists and antagonists. Experimental and clinical observations have demonstrated that pruritus can be evoked or intensified by endogenous or exogenous μ -opioids (272). This phenomenon can be explained by activation of CNS opioid receptors, mainly μ -opioid receptors. Reversing this effect with μ -opioid antagonists thus leads to an inhibition of pruritus (154). The opposite is true for κ -opioids. Their binding to κ -opioid receptors leads to inhibition of pruritus (273).

Several clinical studies have demonstrated that different μ -opioid receptor antagonists may significantly diminish pruritus (43, 50, 274–278). In double-blind RCT, μ -opioid receptor antagonists such as nalmefene, naloxone and naltrexone have exhibited high antipruritic potency. For example, pruritus in chronic urticaria, AD and cholestatic pruritus has shown therapeutic response to nalmefene (10 mg twice daily) and naltrexone (50–100 mg/day) (279, 280). Controlled studies have also been performed in patients with CKD-associated pruritus (37, 38, 281, 282). Results were variable, ranging from significant reduction of pruritus to no response. Naltrexone (50 mg/day) was more effective than placebo on CP in patients with AD (283). Case reports have demonstrated efficacy of naltrexone in several pruritic dermatoses.

Nalfurafine, a preferential κ -opioid receptor agonist, was investigated in CKD-associated CP in two large RCTs (36, 284). Both trials demonstrated significant clinical benefit of nalfurafine in patients with CKD-associated pruritus (273) within the first 7 days of treatment. Similar outcomes in terms of results and adverse drug effects were obtained in an open-label long-term study with 5 mg nalfurafine given orally in 211 haemodialysis patients over a period of 52 weeks (285). In a RCT on 318 patients with refractory cholestatic pruritus nalfurafine (2.5 and 5.0 mg given orally per day) reduced

itch significantly more than placebo as measured on a VAS scale (28.56 and 27.46 vs. 19.25) (286). The drug is currently licensed only in Japan.

Expert recommendation: We suggest mu-opioid receptor antagonists in refractory CP, especially in cholestatic pruritus.

6.4.5. Gabapentin and pregabalin. Gabapentin is an antiepileptic and anxiolytic drug also used in neuropathic pain and pruritus (287). The mechanisms of action of gabapentin, a 1-amino-methyl-cyclo-hexane acetic acid and a structural analogue of the inhibitory neurotransmitter γ -aminobutyric acid (GABA), remain unclear. It is used in postherpetic neuralgia (288), especially with paroxysmal pain or pruritus. Pilot studies have been performed for the treatment of pruritus caused by burns and wound healing in children demonstrating antipruritic effects of gabapentin (289). Double-blind RCTs were performed for CKD-associated pruritus (300 mg thrice weekly or 400 mg twice weekly after haemodialysis sessions) (290, 291) and cholestatic pruritus (292). Gabapentin was safe and effective for treating CKD-associated pruritus (293, 294). It was shown to be effective in 6 cases of brachioradial pruritus, but more disappointing in notalgia paraesthetica (295, 296). An anecdotal indication is cutaneous T-cell lymphoma (297).

Pregabalin is similar to gabapentin and a more recent drug. Its use has been suggested in a case of cetuximab-related pruritus, aquagenic pruritus and in CKD patients unable to tolerate gabapentin (298–300). A controlled trial demonstrated a significant antipruritic effect of pregabalin in patients on haemodialysis within one month (301). In another study on uremic itch, treatment with 75 mg of pregabalin given orally twice weekly in dialysis-dependent patients was compared either to ondansetron or placebo. While a significant effect of pregabalin could be documented, the use of ondansetron and placebo did not yield significant results (302). In an open study 30 patients with CNPG were treated with 75 mg pregabalin per day orally. Treatment improved itch in 76% of patients after a 3-month treatment course (303). Pregabalin 50 mg every other day or 10 mg doxepin given daily for 4 weeks in patients with CKD-associated pruritus led to a significant improvement of pruritus in both groups, but was significantly more effective in patients receiving pregabalin (304).

However, regarding the use of gabapentin or pregabalin an analysis by the US Renal Data System on a large cohort issued a caveat to the use of these drugs. Their use was associated with much higher hazards of altered mental status, falls and fractures (305).

Expert recommendation: We recommend gabapentin and pregabalin in neuropathic CP and in CKD-associated pruritus. We suggest gabapentin and pregabalin for refractory CP and PUO.

6.4.4. Antidepressants. Recent systematic reviews demonstrate evidence that antidepressants are effective particularly in refractory pruritus, pruritus in CKD, cholestasis or neoplasm (306), as well as in other forms of CP (307, 308). Psycho-emotional factors are known to modulate the “itch threshold” (309). Under certain circumstances, they can trigger or enhance CP (310). Itch is a strong stressor and can elicit psychiatric disease and psychological distress. Depressive disorders are present in about 10% of patients with CP (311) and have a clear correlation (312). Antidepressants probably also exert an effect on pruritus through their pharmacological action on serotonin and histamine (306).

The antipruritic action of serotonin reuptake inhibitors (SSRIs) does not start until after 2–3 weeks and the maximum effect is usually seen at 4–6 weeks after initiation of therapy (313); only escitalopram 10–40 mg/day might have a slightly shorter efficacy period. SSRIs such as paroxetine can have an antipruritic effect on patients with PV, psychogenic or paraneoplastic pruritus and other patients with chronic PUO (314, 315). Paroxetine (20 mg/day) has exhibited antipruritic effects in pruritus due to PV (316), paraneoplastic pruritus (317, 318) and psychiatric disease (315, 319). In two patients pruritus was induced by discontinuation of paroxetine treatment for depression (320). An RCT in pruritus of non-dermatologic origin confirmed the antipruritic effect of paroxetine (314). In a two-armed proof-of-concept study with paroxetine and fluvoxamine, patients with CP of dermatological origin reported a significant antipruritic effect (321). Sertraline proved effective in cholestatic pruritus both in adults (322) and children (323), as well as in CKD-associated pruritus (324, 325). In a recent double-blind RCT among 50 haemodialysis patients, sertraline was shown to be effective in reducing uremic pruritus (326), while Doxepin also showed positive effects in 7 patients (304). Doxepin may be administered in a dose from 25–50 mg/day.

Tricyclic antidepressants like doxepin (327) have been effective in urticaria, AD, cutaneous T-cell lymphoma, carcinoma en cuirasse and HIV-related pruritus. It shows almost identical effects compared with hydroxyzine (327). Amitriptyline 25 mg/day has shown a reduction in pruritus in patients with brachioradial pruritus. Trimeprazine and trimipramine are older antidepressants that exhibit some antipruritic effects in AD (328).

Mirtazapine 15–45 mg/day is an atypical antidepressant, both noradrenergic and serotonergic, and has been shown to be effective in the treatment of CP (297, 329, 330). In brachioradial pruritus antidepressants showed moderate effects to decrease pruritus (331).

Side effects of antidepressants are common and include drowsiness, fatigue and headache, mostly initially, but also cardiovascular and gastrointestinal symptoms occur; therefore, caution should be shown in elderly patients

(306). Recommended treatment doses for pruritus in malignant diseases are paroxetine 20–40 mg/day or mirtazapine 15–30 mg/day; for patients with cholestasis or CKD amitriptyline 25–50 mg/day or doxepin 25–20 mg/day.

Expert recommendation: We recommend selected antidepressants (e.g. paroxetine, mirtazapine, doxepin, amitriptyline) for psychogenic CP and for refractory CP, especially in malignant, cholestatic and chronic kidney disease.

6.4.7. Serotonin receptor antagonists. Due to the pathophysiological significance of serotonin in various diseases, e.g. kidney and liver diseases, serotonin receptor antagonists (of the 5-HT₃ type) such as ondansetron (8 mg 1–3x/day), topisetron (5 mg/day) and granisetron (1 mg/day) have been used anecdotally to treat pruritus (332–338). Contradictory or negative results have been reported in partly controlled studies using ondansetron for cholestatic pruritus (332, 339, 340) and opioid-induced pruritus (341–343). An antipruritic effect was reported for ondansetron in CKD-associated pruritus (344). However, this could not be confirmed in subsequent controlled studies (345–347).

Expert recommendation: We recommend against serotonin receptor antagonists in the treatment of CP.

6.4.8. Thalidomide. A number of mechanisms for the antipruritic action of thalidomide have been proposed, including a central depressant effect (348), a local effect on proliferated neural tissue in PN (349) and antagonism of tumour necrosis factor- α (TNF α) (350).

The best results with thalidomide in CP have been achieved in PN. Several studies have shown a rapid decrease in pruritus on thalidomide (50–300 mg/day) (351, 352). In a very recent review the authors refer to how patients were started on higher doses of 200 mg or more daily in earlier studies (353). In the majority of studies since then, however, patients received an initial dose ranging from 50 to 200 mg/day, following which the dosage was tailored according to response or the development of side effects. A prospective open trial of thalidomide 100 mg/day, followed by NB-UVB (TL-01) showed a high response with minimal side effects (354). Likewise, good results have been seen in HIV-positive patients with PN (355). There is one randomised, double-blind cross-over trial of the successful treatment of CKD-associated pruritus with thalidomide (356). Thalidomide is teratogenic and there is a dose-related risk of neuropathy, especially in high daily doses (> 100 mg/day) (357). In most cases the peripheral neuropathy is reversible (353). Thalidomide could be considered particularly in a palliative setting (358).

The scarce information on lenalidomide, a more potent analogue of thalidomide, seems promising (359). More studies are needed to evaluate the effectiveness and tolerability of this analogue of thalidomide.

Expert recommendation: We suggest thalidomide for selected cases of refractory CP after informing the patient about teratogenicity and dose-related risk of neuropathy.

6.4.9. Leukotriene receptor antagonists and TNF α antagonists. Leukotriene receptor antagonists (e.g. montelukast) and TNF α antagonists influence the pathogenesis of AD. They have been used in combination with antihistamines as antipruritic therapy. Montelukast has also been used in several types of urticaria as well as in combination with antihistamines. A combination of H₁-antihistamine with a leukotriene antagonist has been reported to alleviate pruritus in chronic urticaria (348).

Expert recommendation: We suggest against leukotriene receptor antagonists in the treatment of CP.

6.4.10. Cyclosporine, methotrexate, azathioprine and tacrolimus. Controlled clinical studies investigating the efficacy of systemic anti-inflammatory drugs on CP are scarce. Cyclosporine is the only drug that has been approved for the treatment of pruritus in AD (162). The effect of methotrexate and azathioprine on pruritus is mainly documented in retrospective case reports. All these therapies are associated with significant systemic toxicity and require careful patient monitoring. The choice of systemic therapy for CP depends on comorbidities (existing or prior neoplasms or cardiovascular disease), blood tests (haematology, liver and kidney function), age and history of alcohol abuse.

Pruritus in AD responds to treatment with cyclosporine as demonstrated in several double-blind controlled studies (162, 360, 361). Cyclosporine has also proved effective in pruritus associated with refractory chronic urticaria (362). Cyclosporine has been administered in PN for 24–36 weeks, using doses of 3.0–4.5 mg/kg/day. Improvement was observed in both pruritus and skin lesions after 2 weeks of treatment (363, 364). It seems likely that, in these diseases, cyclosporine acts on pruritus through its immunological effects. However, direct effects on nerve endings are also possible (365). Successful use of cyclosporine in non-immunological disease was reported in several studies, e. g. 10 patients with pruritus of senescence were treated with cyclosporine 5 mg/kg/day for 8 weeks (366). All patients in this uncontrolled, open study responded. Case reports describe antipruritic effects in dystrophic epidermolysis bullosa-associated CP (367).

Methotrexate, licensed for psoriasis, has proved effective for psoriasis-associated pruritus (368). Patients with severe AD refractory to topical therapy may respond to methotrexate with greatly reduced pruritus (162, 369). In a retrospective report on 13 patients with CNPG, 10 markedly improved on methotrexate at doses of 7.5–20 mg once weekly for a minimum of 6 months (370). In a recent multicenter study, a 90% overall response rate was reported in 39 patients with difficult-to-treat prurigo using methotrexate with a median weekly dose of 15 mg (371).

Azathioprine, licensed as a corticosteroid-sparing drug for blistering diseases, has proved effective in pruritus associated with bullous pemphigoid in doses of 50–200 mg/day (372). Patients with severe AD refractory to topical therapy may respond to azathioprine with greatly reduced pruritus (162, 369). In a retrospective review 96 patients with life-altering CP who had previously responded to systemic steroids were reported. A daily azathioprine dose ranging from 25 to 275 mg resulted in relief of pruritus with a reduction in VAS from 9.2 prior to treatment to 1.6 post treatment. The mean duration of therapy in this study was 53 months and 33% of the patients were forced to discontinue treatment due to adverse drug effects (373).

Data on systemic treatment with tacrolimus in CP are sparse. Besides case reports (374), one open-label study on a sequential treatment with oral (6 weeks) and topical tacrolimus (11 weeks) in 12 patients with severe AD resulted in a substantial reduction in pruritus (375). In contrast to these results, a case series in 4 patients with AD treated with 5 mg tacrolimus twice daily for 14 months showed poor results in 3 of the patients (376). *Expert recommendation:* We suggest cyclosporine, methotrexate and azathioprine for refractory CP associated with inflammatory dermatoses and CPG.

6.4.11. Neurokinin receptor 1 antagonist. Substance P (SP) plays a dominant role in pruritus induction after release from cutaneous sensory neurons. Via binding to the neurokinin 1 receptor (NK1R) on keratinocytes, blood vessels and mast cells, SP promotes inflammation and mast cell degranulation. Cutaneous SP levels are increased in conditions with hyperplasia of skin nerves (AD, PN). Accordingly, inhibition of the pruritogenic effects of SP by blocking the corresponding receptor may have antipruritic effects. Several case series and case reports suggest a positive role of the NK1R antagonist aprepitant in CP, e.g. cutaneous T-cell lymphoma, solid tumours, drug-induced pruritus, CP with atopic predisposition and CNPG (377–382). However, recent controlled trials including a randomized double-blind, placebo-controlled phase-II study using topical or systemic aprepitant failed to show a benefit compared to placebo (383–385). Serlopitant is a novel NK1R antagonist that can be administered for long-term therapy. RCTs demonstrated a significant effect on pruritus of CPG and was well tolerated (386, 387).

Expert recommendation: We suggest NK1R antagonists such as serlopitant in refractory CP and CPG.

6.4.12. Biologics. Biologic therapies have burst onto the armamentarium to treat CP in certain cutaneous diseases. In addition, some biologic approaches have been developed to control CP alone. This is the case with omalizumab for CSU. This humanized recombinant monoclonal antibody binds specifically to the Cε3 domain of the immunoglobulin E (IgE) heavy chain. Omalizumab reduces

the levels of free IgE and the density of the high-affinity IgE receptor, both of which are essential in mast cell and basophil activation and consequently degranulation (388). Omalizumab was approved in 2014 in Europe (300 mg) and the US (150 and 300 mg), administered subcutaneously every 4 weeks for recalcitrant chronic spontaneous urticaria refractory to H1-antihistamines in adults and children (aged 12 years and above). The itch severity score was the primary endpoint assessed in the phase III clinical trials. Omalizumab showed effective and rapid reduction of itch in a dose-dependent manner that was maintained over the treatment period. An improvement in the number of hives, need for emergency medication and quality of life of patients with chronic spontaneous urticaria, as well as good tolerance and safety profiles, were also reported (389–391). A clinically relevant response is seen within a few weeks of initial administration. Side effects are usually mild or moderate and include mainly headache, nasopharyngitis, myalgia and local symptoms at the injection site.

With regard to AD, monoclonal antibodies that block signalling of both IL-4 and IL-13, key T helper cell 2 (Th2) cytokines, are in development. Dupilumab, a fully human monoclonal antibody directed against the IL-4 receptor α (IL-4R α), has been shown to be efficient in controlling patients' assessment of CP as measured by the pruritus NRS score at week 16, with a significant reduction of pruritus seen as early as week 1 (dupilumab 300 mg once a week) in severe adult AD patients in the phase 2b trial (392). A number of trials are currently ongoing with different targets such as IL-31, IL-22, TSLP and CRTH.

Pruritus-reducing effects of biologic treatment on psoriatic pruritus have been reported (393–401). One single report of cases referred to persistent CP (402). Secukinumab significantly improved CP in a phase 3 study (398). Ixekizumab showed long-term effects on CP in psoriasis in a phase 3 clinical trial and maintenance therapy sustained improvements in psoriasis severity over more than 1 year (397, 400). According to a systematic review anti-IL 17, JAK inhibitors, adalimumab, and apremilast are effective in reducing CP in psoriasis, with anti-IL-17 showing the largest effect in reducing psoriasis (401).

According to the different pathogenic mechanisms involved in pruritus, potential new monoclonal antibodies will be developed that, e.g. target Na V1.7, a voltage sensor for pain and itch relief (403). However, these developments lie in the future.

Expert recommendation: We suggest omalizumab for refractory CP in CSU and dupilumab for refractory CP in AD. We cannot make a recommendation with respect to the use of monoclonal antibodies in CP of other origin.

6.4.13. Physical treatment modalities. Physical treatments such as transcutaneous electrical (field) stimulation and acupuncture have been described for the treatment

of CP (404, 405). Acupuncture is the oldest and best studied alternative option with evidence-based effect on pain, but much less evidence of its antipruritic effects. A few placebo-controlled experimental studies have shown that local treatment with acupuncture needling reduces histaminergic itch in healthy volunteers and allergen-induced itch in patients with AD (406–408). The effect of acupuncture on sensory innervation in the skin was investigated in 10 subjects that were treated with 10 acupuncture needles subcutaneously during twice-weekly 25-min sessions over 5 weeks and skin biopsies revealed reduced density of sensory nerve fibres (409). In a retrospective study, symptomatic relief of neuropathic pruritus (brachioradial CP, notalgia paresthetica, meralgia paresthetica) in 12 of 16 patients treated with acupuncture was reported (410). Relapse occurred in 37% of patients within 1–12 months following treatment. In a placebo-controlled study of 6 patients with intractable pruritus in CKD, electrical needle stimulation at the point of the elbow reduced severity, frequency and distribution of itch both day and night (410), while control treatment with superficial electrical stimulation was ineffective. Che-Yi et al. randomised 40 patients with refractory uremic pruritus into two groups: acupuncture needling was applied either unilaterally at the acupoint of the elbow or at a non-acupoint (control). The patients were treated 3 times weekly for 1 month. At the end of the treatment period and at 3 months follow-up, only the acupoint group showed a 50% reduction in pruritus (411). The rationale for the use of acupuncture in the treatment of itch, as well as its effects in uremic pruritus and allergic diseases has been reviewed (409, 412, 413).

A double-blind randomised placebo-controlled study in 30 patients with AD revealed that acupuncture achieved a significant reduction of itch (414). In another study in 40 patients with refractory UP, an acupuncture needle was inserted at the Quchi acupoint and then removed after 1 h. Patients undergoing this treatment showed a substantial improvement in itch compared to controls (411).

Transcutaneous electrical nerve stimulation (TENS), which activates electrically myelinated nerve fibres (α and δ), is widely used for the treatment of chronic pain (415). Fjellner & Hägermark studied the effect of TENS on CP of various origin in 41 patients for 5–47 days. Initially, TENS ameliorated pruritus in 63% of patients, but the effect declined over the course of therapy and was regarded as placebo (416).

Another technique, cutaneous field stimulation (CFS), was developed to electrically stimulate unmyelinated C-fibres at the dermo-epidermal junction in order to treat pruritus (417). In an experimental study on 21 subjects, the pruritus induced by histamine iontophoresis was completely abolished by CFS (417). In a controlled study, 27 atopic patients with CP were treated with CFS and TENS (418), CP was significantly suppressed for 7 h after cessation of CFS, but not after TENS.

In an open trial on 19 patients (16 patients with neuropathic pruritus and 3 patients with generalized pruritus) using CFS once daily for 25 min for 5 weeks, pruritus was reduced by 49% at the end of treatment (419). Skin biopsies revealed a significant reduction in epidermal nerve fibres following the treatment (419). In this study, pruritus relapsed gradually after discontinuation of CFS, indicating nerve fibre regeneration in the epidermis.

Expert recommendation: We cannot make a recommendation with respect to physical treatment for the treatment of CP.

6.5. Ultraviolet phototherapy

UV-based therapy is well established for treating pruritus and utilizes UVB (290–320 nm) and UVA (320–400 nm). The light sources include broadband UVB (BB-UVB, 290–320 nm, peaks at 313 nm), narrowband UVB (NB-UVB, 311 nm), broadband UVA (320–400 nm, peaks at 355 nm) and UVA1 (340–400 nm, peaks at 365 nm) (420). Immunomodulatory effects due mostly to the release of anti-inflammatory neuropeptides, or the inhibition of pro-inflammatory mediators (e.g. IL-1, TNF α), make these different UV treatments particularly useful for treating pruritus associated with inflammatory dermatoses (421).

For the treatment of AD, phototherapy is a common and valid treatment, inhibiting pruritus by reducing numbers of nerve fibres in the epidermis and normalising the expression of axonal guidance molecules (e.g. nerve growth factor, semaphorin 3A) in atopic skin (422, 423). Treatment with phototherapy can improve, or even resolve, AD with remission of up to 6 months and no reported serious adverse effects in the short-term (5). Preference is given to UVA-1 and NB-UVB as modalities, since both have been found to be equally effective in improving pruritus of AD, although it is noted that NB-UVB has the dual advantage of less heat load and shorter duration of phototherapy (424, 425). Systemic PUVA has also been shown to effectively treat the itch of AD, but with side effects including burning, pain, nausea, headache, erythema and lentigenes (426). A study comparing bath-PUVA with NB-UVB found both to be very effective measures, reporting that relief from pruritus was usually achieved in the first 2 weeks, and consistently preceded the resolution of skin lesions (427).

UVB laser may be still more effective than NB-UVB, with localised AD and associated pruritus being successfully treated with 308-nm xenon chloride excimer laser (428).

Both AD and lichen amyloidosis have been successfully treated by combinations of NB-UVB with steroids or cyclosporine A (421).

For the treatment of CPG, PUVA, UVA1 and NB-UVB proved to be effective in a RCT, with PUVA and UVA1 superior to NB-UVB (429).

For many other skin diseases, a number of studies have demonstrated the efficacy of UV treatment, e.g. psoriasis, lichen planus, T-cell lymphoma, solar, chronic and idiopathic urticaria, as well as urticaria pigmentosa and folliculitis of pregnancy (421, 430). UVB mainly affects epidermal keratinocytes and Langerhans cells, due to its limited penetration into the skin. UVA1, in contrast, reaches to the dermis and therefore can affect T lymphocytes, mast cells and dermal dendritic cells, e.g. induces apoptosis of these cells (420). However, UVB-induced apoptosis of mast cells has been postulated to explain relief of pruritus (431). Furthermore, phototherapy leads to a reduction in CGRP-immunoreactive nerve fibres in the skin (432). No further benefit has been found by adding UVA in combination with NB-UVB phototherapy for the treatment of pruritic inflammatory skin disease (433). A novel treatment that has proven beneficial in pilot studies is a topical cream that filters solar UVB (434). This has the advantage of saving time, inconvenience and expense associated with traditional UV therapy.

Pruritus associated with mastocytosis can be treated with oral PUVA, although alleviation is only short-term, or with NB-UVB if PUVA is not tolerated (435).

UV phototherapy has been used with some success in conditions with pruritus on primarily non-inflamed or normal appearing skin. It has been particularly effective in many cases of CKD-associated pruritus (224, 436, 437). In an open pilot study using NB-UVB 14/20, CKD-associated pruritus patients responded well to treatment (438). Also in a recent study NB-UVB appeared to be effective in the reduction of CKD-associated pruritus (439). However, a later RCT failed to demonstrate a significant difference in the reduction of pruritus intensity in patients receiving NB-UVB compared with a control group (440). In another case NB-UVB treatment was unsuccessful, but BB-UVB helped (441). For end-stage renal disease BB-UVB is recommended at a frequency of 3 times per week, tapering to one or two maintenance sessions per week to achieve control of pruritus (442).

UV therapy has also been reported to be effective in a number of cases of pruritus associated with other systemic diseases, including hepatic and metabolic disorders, as well as malignancy (443). BB-UVB was found to reduce cholestatic-induced pruritus in 10/13 patients (444). In polycythemia vera, 8/10 patients responded to NB-UVB in an open study (445). In a single case report a patient with Hodgkin's disease responded well to BB-UVB (446).

Aquagenic pruritus showed response to bath-PUVA therapy (447) and systemic PUVA (448, 449) for the duration of therapy. To treat aquagenic pruritus, PUVA was found to be superior to BB-UVB in 5 patients (450). Recently, two patients with aquagenic pruritus were reported to show a good, but transient response to NB-UVB (451). In HIV patients with pruritus, UVB produced significant relief of pruritus in an open study

with 21 patients (33% primary pruritus, 66% eosinophilic folliculitis) (452). Phototherapy has been useful in treating idiopathic pruritus in some HIV patients, as well as HIV-associated dermatoses (453).

Common adverse effects of UVB phototherapy are tanning and erythema. Both UVA and UVB have been associated with skin ageing. The potential carcinogenic effect of phototherapy is of concern. In general, the use of UVB has shown no or little association with skin cancer and is considered a very safe treatment option (454, 455). However, studies of PUVA-treated patients and associated cancer risk have reported increased incidence of melanoma (particularly squamous cell carcinoma) and recommend careful selection of patients with rigorous follow-up (456, 457).

Expert recommendation: We suggest UVA and UVB (NB-UVB/BB-UVB) phototherapy for refractory CP in inflammatory skin diseases, cutaneous lymphoma CPG and selected cases of systemic pruritus (e.g. CKD-associated pruritus, cholestatic pruritus, aquagenic pruritus). We suggest UV phototherapy in combination with topical and/or systemic treatment, with the exception of calcineurin inhibitors and immunosuppressant drugs.

6.6. Treatment in special populations

6.6.1. Treatment of chronic pruritus in the elderly. Elderly patients with CP require special attention, even though the general principles of treatment apply. The older patient with CP characteristically presents a mixed clinical picture of comorbidities and polypharmacy, including physical and cognitive limitations; some degree of xerosis cutis is omnipresent in most cases (458–460). Any underlying condition such as CKD, hepatobiliary disease or malignancies should be addressed primarily (460). Treatment is therefore challenging and needs to be tailored to each case.

The application of topical soothing agents and, if required, anti-inflammatory treatment are recommended for the management of xerosis. Fingernails should be kept short and soap should be avoided or restricted to the axilla, groin, scalp and soles, preferably using acidic pH soap. Furthermore, less frequent bathing, preferably in tepid water, and the avoidance of astringents and lactic acid (>5%) are also recommended. The application of petroleum-containing moisturisers immediately after bathing is helpful. More aggressive hydration might be necessary: after a 20-min soak, an effective moisturiser is applied on patted-dry skin, which is then covered with kitchen clingfilm (plastic wrap) or a moist garment. This technique is called the "soak and smear" method (458, 461). Oatmeal baths can also be useful, likely due to the anti-inflammatory properties of oatmeal (462). Other topical treatments with urea solutions, menthol, pramoxine, pimecrolimus, tacrolimus and topical amitriptyline-ketamine with lidocaine can be beneficial;

however, topical corticosteroids should be avoided on elderly skin due to skin thinness.

Systemic treatment of CP in an elderly patient demands special caution. Second-generation non-sedating antihistamines may be useful, but first-generation sedating antihistamines should be avoided, as well as tricyclic antidepressants such as doxepin due to anticholinergic effects. Long-term systemic steroids should also be avoided, since impaired immunity and comorbidities are often present in the elderly patient (460). The anti-epileptic drugs gabapentin and pregabalin are useful, but dizziness and sedation may occur with increasing dose. In elderly patients, lower dosages of gabapentin and pregabalin are usually sufficient to control CP. The tetracyclic antidepressant mirtazapine can be effective against nocturnal itch (463). SSRIs such as paroxetine and fluvoxamine are also effective in the elderly, but can exacerbate sexual dysfunction and insomnia (460). Sertraline is a good option for the treatment of cholestatic itch. The use of μ -opioid receptor antagonists and κ -opioid receptor agonists should be approached with caution as a result of hepatotoxicity, gastrointestinal symptoms and dizziness. Thalidomide might be a good option for the elderly patient with chronic itch (460). Successful use of cyclosporine was reported in several studies, e. g. 10 patients with pruritus of senescence were treated with cyclosporine 5 mg/kg per day for 8 weeks (366).

UV phototherapy is an option in the elderly; however, caution must be taken in case of increased photosensitivity or phototoxicity caused by multiple drug ingestion (229). Overall, phototherapy such as NB-UVB (TL01) is a good treatment option, since it can avoid further polypharmacy; however, skin cancer needs to be borne in mind. Phototherapy in the elderly depends on the patient's mobility. In summary, treatment of pruritus in the elderly is primarily focused on efficient hydration of the skin. Caution should be shown with systemic therapy due to polypharmacy, interactions and adverse effects.

6.6.2. Treatment of chronic pruritus in pregnancy. Due to potential effects on the foetus, the treatment of pruritus in pregnancy requires prudent consideration of whether the severity of the underlying disease warrants treatment and careful selection of the safest treatments available. Topical corticosteroids are the most frequently used drugs for treating skin conditions and are prescribed to more than 6% of pregnant women (464). However, little is known about the effects of local corticosteroids on the foetus.

According to a very recent Cochrane review update, there are no causal associations between maternal exposure to topical corticosteroids of all potencies and pregnancy outcomes, including mode of delivery, congenital abnormalities, preterm delivery, fetal death and low Apgar score (465). A recent study showed a significantly increased risk of low birth weight in cases where more than 300 g of potent or very potent topical

corticosteroids were applied over the course of the entire pregnancy (464). Systemic treatments such as systemic glucocorticosteroids, a limited number of antihistamines and UV phototherapy, e.g. UVA, may be necessary in severe and generalised forms of CP in pregnancy. UV phototherapy is a useful alternative therapy for pruritus during pregnancy that is refractory to steroids or antihistamines (421).

There is a lack of knowledge concerning the pharmacokinetics of the use of antihistamines during pregnancy. The use of first-generation antihistamines is to be avoided in pregnant women (257); on the other hand, they are also considered safe on the basis that they have already been prescribed for a very long time. Of the second-generation antihistamines, loratadine and cetirizine are the best studied (466). They can be prescribed after the first trimester in the case of well-considered indications. Administration immediately prior to or after birth must be avoided. NB as well as BB UVB phototherapy is safe; however, since folic acid levels may decrease with both (467), follow-up of folic acid levels is indicated. In summary, the treatment of pruritus in pregnancy is primarily focused on topical treatment in order to relieve CP, possibly complemented by UV phototherapy. Caution should be shown with systemic therapy due to possible effects on the foetus.

6.6.3. Treatment of chronic pruritus in children. The management of CP in children is based on the diagnosed systemic or skin condition. Nevertheless, some general considerations must be taken into account once topical or systemic drugs are used, such as the body volume/body surface area rate and the total weight. In addition, the licensed age for any drug must be taken into account. Individualised management is recommended.

Topical treatments for pruritus should be focussed on the cause if possible. Avoidance of the specific and non-specific provocation factors is necessary. Such factors include, e.g.: inhalants, microbial agents, foods, textiles, chemicals and emotional stress. The use of emollients in an attempt to preserve barrier function is always required. Low- (class 1, 2) to medium-strength (class 3) glucocorticosteroids may be administered in children. Topical immunomodulators are used for AD and pruritus in children aged 2 years and older, but in some European countries pimecrolimus, for instance, is licensed for use in children older than 3 months. Topical capsaicin is not used in children <10 years. New topical active principles are in development for CP in children, such as a 4% cutaneous emulsion of sodium cromoglicate (468) or a 2% topical ointment of crisaborole (phosphodiesterase-4 inhibitor) (469).

The dosages of systemic drugs need to be adjusted in children. The most common drugs used to control pruritus in AD and CSU in children is an H1-receptor inverse agonist. The common use of first-generation antihistamines (e.g. hydroxyzine dichlorhydrate) to

avoid scratching during the night in AD has long been discussed based on the controversial role of histamine in dermatitis and on the defined adverse events, e.g. drowsiness and impaired attention. There is no mechanistic rationale for treating non-histaminergic pruritus-related AD with antihistamines (120). The treatment of CSU in infants and children is based on the use of second-generation H1-antihistamines according to the same algorithm recommended for adults (158, 470). Cetirizine, desloratadine, fexofenadine, levocetirizine and loratadine have been studied in children and their long-term safety has been well established in the paediatric population. Rupatadine has been recently approved for the treatment of CSU in children aged 2–11 years old based on a double-blind trial showing safe efficacy with respect to placebo at 1 mg/ml (256). Certain antihistamines (e.g. loratadine, ceterizine) are thought to be safer for use in children, and thus may be preferred in these patients (206). In children aged under 6 years the effective dose of hydroxyzine is up to 50 mg/day in divided doses, and 50–100 mg/day in children aged 6–12 years (243). In summary, for the paediatric management of pruritus, long-term use of first-generation antihistamines is not recommended (158, 208). The associated psychomotor impairment may impact the education and safety of children and persists even after the child has become accustomed to the sedating effects (258). Second-generation antihistamines with appropriate dose adjustment are first-line therapy for CP in children such as urticaria (259).

Other therapies could also be considered, such as UV phototherapy, but the indication and protocol should be carefully considered together with the family due to possible long-term photo damage to the skin. A retrospective analysis of children up to the age of 18 years suffering from AD and psoriasis suggests NB-UVB treatment (471). In children, longer follow-up is essential to determine the true carcinogenic risk of UV therapy. An adjuvant psychological intervention as well as an educational approach can also be highly useful in children (120).

Other systemic treatments such as cyclosporine are not licensed in children younger than 16 years due to a lack of clinical studies. They may be used in treatment-refractory cases (110).

In summary, the treatment of pruritus in children is primarily focused on treatment of the skin disease, especially AD. Topical corticosteroids, topical immunomodulators and some antihistamines can be administered in children, but national regulations must be considered. UV phototherapy may be initiated depending on the child's skin type and age. Caution should be shown with systemic therapy due to the lack of data and off-label use in children.

6.7. Psychosomatic therapy (relaxation techniques and psychotherapy)

The vicious itch–scratch cycle needs to be considered when a patient is treated for CP. The psychosomatic approach recognises the pruritus patient with regard to coping behaviour and possible stress attempts as cause or provocation factors in CP. Essentially, psychosomatic treatment could complement topical and systemic therapy and should be differentiated into unimodal psychological treatment and multimodal psychological treatment for CP (97). Depending on the factors involved, a unimodal (progressive muscular relaxation, autogenic training) or multimodal psychological approach is recommended (97). In addition to causal and symptomatic therapy, behavioural therapy to avoid scratching should be considered, e. g. conscious suppression of the reflex by intense concentration, distraction or alternative scratching techniques such as habit reversal (472). This is very important in patients with CPG who might show unconscious automatic scratching behaviour.

Adjuvant psychosocial programmes focused on CP are most effective in AD (122, 473–475). Such programmes include strategies for breaking the vicious circle of itching and scratching, relaxation and stress management techniques, as well as strategies for dealing with relapses. There are more than 10 RCTs showing slightly beneficial effects; these were recommended for treatment by a Cochrane review on psychological interventions (476). A similar educational programme was developed for patients with CP (477, 478). It is currently established for in-patient hospital treatment of patients with pruritic dermatoses using behavioural therapy in the context of an integrated psychosomatic treatment (479, 480). In patients with coexisting depression, psychotherapy in combination with psychotropic medication can be helpful even to treat CP of different aetiology (481). Most publications on psychotherapeutic/ psychopharmacologic interventions, however, refer to small groups or single case reports. In neurotic excoriations, combined psychopharmacotherapy is also often indicated (481–484). Internet-delivered (eHealth) self-management was investigated in recent years, mostly with cognitive behavioural interventions. Results demonstrate effects similar to face-to-face psychotherapy (485). Studies specifically for dermatologic patients are promising (486).

Expert recommendation: We recommend educational programs. We suggest relaxation and habit reversal techniques as a complementary treatment for managing CP.

7. KEY SUMMARY OF DISCUSSION

- Chronic pruritus is frequent in medicine and needs a precise diagnostic work-up. Its management compri-

ses treatment of the underlying disease, topical treatment modalities including symptomatic antipruritic treatment, UV phototherapy and systemic treatments.

- Sedative or non-sedating H1 antihistamines are suggested as an initial symptomatic therapy in severe CP and sleep loss. Studies on the systemic administration of higher doses of non-sedating antihistamines seem to be promising, but RCTs need to be conducted.
- Systemic glucocorticosteroids are not recommended for first-line treatment of CP, with the exception of extremely severe and acute cases of inflammatory dermatoses and as a short-term treatment in selected cases of refractory CP, especially in paraneoplastic pruritus and palliative care.
- UV phototherapy is recommended for refractory CP in inflammatory skin diseases, cutaneous lymphoma, CPG and selected cases of systemic pruritus (e.g. CKD-associated pruritus, cholestatic pruritus, aquagenic pruritus), especially in elderly pruritus patients or in case of contraindications for systemic therapy. We suggest UV phototherapy in combination with topical and/or systemic treatment, with the exception of calcineurin inhibitors and immunosuppressant drugs.
- Gabapentinoids (gabapentin, pregabalin) are recommended in neuropathic CP and in CKD-associated pruritus and suggested for the treatment of refractory CP and PUO.
- We suggest μ -opioid receptor antagonists in refractory CP, especially in cholestatic pruritus.
- Selected antidepressants are recommended for psychogenic CP and for refractory CP, especially in malignant, cholestatic and chronic kidney disease.
- Neurokinin receptor 1 antagonists like e.g. serlopitant can be recommended in refractory CP and CPG.
- Serotonin receptor antagonists are not recommended for the treatment of CP and CPG.

ACKNOWLEDGEMENTS

We thank Mrs Christine Schaefer for her help with editing, language correction and arranging the list of references.

Conflict of Interest: see Appendix S1¹.

Composition of the guideline group: Experts in the field from Europe. More than 30% are European Academy of Dermatology and Venereology (EADV) members.

8. REFERENCES

1. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. *Acta Derm Venereol.* 2009;89(4):339-50.
2. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. *J Eur Acad Dermatol Venereol.* 2010;24(3):317-28.
3. Misery L, Alexandre S, Dutray S, Chastaing M, Consoli SG, Audra H, et al. Functional itch disorder or psychogenic pruritus: suggested diagnosis criteria from the French psychodermatology group. *Acta Derm Venereol.* 2007;87(4):341-4.
4. Magerl M, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, et al. The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. *Allergy.* 2009;64(12):1715-21.
5. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. *J Eur Acad Dermatol Venereol.* 2016;30(5):729-47.
6. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. *Allergy.* 2018.
7. Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. *J Eur Acad Dermatol Venereol.* 2017;31(8):1248-53.
8. Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, et al. Pharmacological interventions for pruritus in adult palliative care patients. *Cochrane Database Syst Rev.* 2016;16(11):CD008320.
9. Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. *Acta Derm Venereol.* 2007;87(4):291-4.
10. Ständer S, Weisshaar E, Mettang T, Streit M, Darsow U, Schneider G, et al. [Clinical classification of chronic pruritus. Interdisciplinary consensus proposal for a diagnostic algorithm]. *Hautarzt.* 2006;57(5):390-4.
11. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, et al. Itch: scratching more than the surface. *QJM.* 2003;96(1):7-26.
12. Oaklander A. Common neuropathic itch syndromes. *Acta Derm Venereol.* 2012;92(2):118-25.
13. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. *Br J Prev Soc Med.* 1976;30(2):107-14.
14. Zyllic Z, Twycross R, Jones EA. Pruritus in advanced disease. Oxford: Oxford University Press; 2004.
15. Dalgard F, Svensson A, Holm JO, Sundby J. Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. *Br J Dermatol.* 2004;151(2):452-7.
16. Dalgard F, Dawn AG, Yosipovitch G. Are itch and chronic pain associated in adults? Results of a large population survey in Norway. *Dermatology.* 2007;214(4):305-9.
17. Matteredne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Buttner M, Ofenloch R, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. *Acta Derm Venereol.* 2011;91(6):674-9.
18. Matteredne U, Apfelbacher CJ, Vogelgsang L, Loerbroks A, Weisshaar E. Incidence and determinants of chronic pruritus: a population-based cohort study. *Acta Derm Venereol.* 2013;93(5):532-7.
19. Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. *Dermatology.* 2010;221(3):229-35.
20. Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. *Int J Dermatol.* 2002;41(4):212-6.
21. Szepietowski JC, Reich A, Wisnicka B. Itching in patients suffering from psoriasis. *Acta Dermatovenerol Croat.* 2002;10(4):221-6.
22. Szepietowski JC, Reich A, Wisnicka B. Pruritus and psoriasis. *Br J Dermatol.* 2004;151(6):1284.
23. Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem. *J Am Acad Dermatol.*

¹<https://doi.org/10.2340/00015555-3164>

- 2004;51(5):842-3.
24. Weiss M, Mettang T, Tschulena U, Weisshaar E. Health-related quality of life in haemodialysis patients suffering from chronic itch: results from GEHIS (German Epidemiology Haemodialysis Itch Study). *Qual Life Res.* 2016;25(12):3097-106.
 25. Ferm I, Sterner M, Wallengren J. Somatic and psychiatric comorbidity in patients with chronic pruritus. *Acta Derm Venereol.* 2010;90(4):395-400.
 26. Britt H, Pan Y, Miller GC, Valenti L, Charles J, Knox S, et al. Presentations of 'itch' in Australian general practice. *Aust Fam Physician.* 2004;33(7):488.
 27. McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice. Fourth national study 1991-1992. London: Her Majesty's Stationery Office; 1995.
 28. Symvoulakis EK, Krasagakis K, Komninos ID, Kastrinakis I, Lyronis I, Philalithis A, et al. Primary care and pattern of skin diseases in a Mediterranean island. *BMC Fam Pract.* 2006;7:6.
 29. Frese T, Herrmann K, Sandholzer H. Pruritus as reason for encounter in general practice. *J Clin Med Res.* 2011;3(5):223-9.
 30. Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. *J Eur Acad Dermatol Venereol.* 2018;32(7):1059-65.
 31. Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. *Nephrol Dial Transplant.* 2006;21(3):749-55.
 32. Blachley JD, Blankenship DM, Menter A, Parker TF, 3rd, Knochel JP. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. *Am J Kidney Dis.* 1985;5(5):237-41.
 33. Stahle-Backdahl M, Hagermark O, Lins LE, Topping O, Hilliges M, Johansson O. Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus. *J Intern Med.* 1989;225(6):411-5.
 34. Stockenhuber F, Sunder-Plassmann G, Balcke P. Increased plasma histamine levels in chronic renal failure. *N Engl J Med.* 1987;317(6):386.
 35. Dugas-Breit S, Schopf P, Dugas M, Schiffl H, Rueff F, Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. *J Dtsch Dermatol Ges.* 2005;3(5):343-7.
 36. Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. *J Am Soc Nephrol.* 2005;16(12):3742-7.
 37. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, et al. Randomised crossover trial of naltrexone in uraemic pruritus. *Lancet.* 1996;348(9041):1552-4.
 38. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. *J Am Soc Nephrol.* 2000;11(3):514-9.
 39. Duque MI, Thevarajah S, Chan YH, Tuttle AB, Freedman BI, Yosipovitch G. Uremic pruritus is associated with higher kt/V and serum calcium concentration. *Clin Nephrol.* 2006;66(3):184-91.
 40. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus--new perspectives and insights from recent trials. *Nephrol Dial Transplant.* 2002;17(9):1558-63.
 41. Wang CP, Lu YC, Tsai IT, Tang WH, Hsu CC, Hung WC, et al. Increased Levels of Total p-Cresylsulfate Are Associated with Pruritus in Patients with Chronic Kidney Disease. *Dermatology.* 2016;232(3):363-70.
 42. Hayani K, Weiss M, Weisshaar E. Clinical Findings and Provision of Care in Haemodialysis Patients with Chronic Itch: New Results from the German Epidemiological Haemodialysis Itch Study. *Acta Derm Venereol.* 2016;96(3):361-6.
 43. Bergasa NV. The pruritus of cholestasis. *J Hepatol.* 2005;43(6):1078-88.
 44. Beuers U, Kremer AE, Bolier R, Elferink RP. Pruritus in cholestasis: facts and fiction. *Hepatology.* 2014;60(1):399-407.
 45. Kremer AE, Bolier R, van Dijk R, Oude Elferink RP, Beuers U. Advances in pathogenesis and management of pruritus in cholestasis. *Dig Dis.* 2014;32(5):637-45.
 46. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. *Baillieres Best Pract Res Clin Gastroenterol.* 2000;14(4):643-55.
 47. Kremer AE, Namer B, Bolier R, Fischer MJ, Oude Elferink RP, Beuers U. Pathogenesis and management of pruritus in PBC and PSC. *Dig Dis.* 2015;33(Suppl 2):164-75.
 48. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42(10):2204-12.
 49. Kremer AE, Dijk RV, Leckie P, Schaap FG, Kuiper EM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. *Hepatology.* 2012.
 50. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalme-fene therapy for the pruritus of cholestasis. *Hepatology.* 1998;27(3):679-84.
 51. Neilly JB, Martin A, Simpson N, MacCuish AC. Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control. *Diabetes Care.* 1986;9(3):273-5.
 52. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. *Am J Clin Dermatol.* 2003;4(5):315-31.
 53. Caravati CM, Jr., Richardson DR, Wood BT, Cawley EP. Cutaneous manifestations of hyperthyroidism. *South Med J.* 1969;62(9):1127-30.
 54. Adams S. Iron deficiency, serum ferritin, generalized pruritus and systemic disease: a case control study. *Br J Dermatol.* 1989;121(s34):15.
 55. Nestler JE. Hemochromatosis and pruritus. *Ann Intern Med.* 1983;98(6):1026.
 56. Hamilton DV, Gould DJ. Generalized pruritus as a presentation of idiopathic haemochromatosis. *Br J Dermatol.* 1985;112(5):629.
 57. Wahid Z, Kanjee A. Cutaneous manifestations of diabetes mellitus. *J Pak Med Assoc.* 1998;48(10):304-5.
 58. Weisshaar E, Weiss M, Mettang T, Yosipovitch G, Zyllicz Z. Paraneoplastic itch: An expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). *Acta Derm Ven* 2015;95:261-165.
 59. Kilic A, Gul U, Soylu S. Skin findings in internal malignant diseases. *Int J Dermatol.* 2007;46:1055-60.
 60. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. *Blood Cancer Journal.* 2018;8(1):3.
 61. Bernhard JD. Itch: Mechanisms and management of pruritus. New York: McGraw-Hill; 1994.
 62. Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. *J Invest Dermatol.* 2013;133(12):2783-5.
 63. Diehn F, Tefferi A. Pruritus in polycythemia vera: prevalence, laboratory correlates and management. *Br J Haematol.* 2001;115(3):619-21.
 64. Egli F, Wieczorek A, Niemoller M, Rhyner K. [Polycythemia vera: clinical aspects and course in 86 patients]. *Schweiz Med Wochenschr.* 1988;118(52):1969-75.
 65. Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. *Blood.* 1966;28(6):795-806.
 66. Siegel FP, Tauschert J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. *Am J Hematol.* 2013; 88:665-9.
 67. Krajnik M, Zyllicz Z. Pruritus in advanced internal diseases. Pathogenesis and treatment. *Neth J Med.* 2001;58(1):27-40.
 68. Brunner W. [Pruritus--also a challenge in internal medicine]. *Schweiz Med Wochenschr.* 1995;125(46):2244-50.
 69. Fett N, Haynes K, Robert KJ, Margolis DJ. Five-year malignancy incidence in patients with chronic pruritus: a popu-

- lation-based cohort study aimed at limiting unnecessary screening practices. *J Am Acad Dermatol.* 2014;70:651-8.
70. Johannesdottir SA, Farkas BK, Vinding GR, Pedersen L, Lamberg A, Sorensen HT, et al. Cancer incidence among patients with a hospital diagnosis of pruritus: a nationwide Danish cohort study. *Br J Dermatol.* 2014;171(4):839-46.
 71. Serling SLC, Leslie K, Maurer T. Approach to pruritus in the adult HIV-positive patient. *Semin Cutan Med Surg.* 2011;30(2):101-6.
 72. Kaushik SB, Cerci FB, Miracle J, Pokharel A, Chen SC, Chan YH, et al. Chronic pruritus in HIV-positive patients in the southeastern United States: its prevalence and effect on quality of life. *J Am Acad Dermatol.* 2014;70(4):659-64.
 73. Weisshaar E, Apfelbacher C, Jager G, Zimmermann E, Bruckner T, Diepgen TL, et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. *Br J Dermatol.* 2006;155(5):957-64.
 74. Afifi Y, Aubin F, Puzenat E, Degouy A, Aubrion D, Hassam B, et al. [Pruritus sine materia: a prospective study of 95 patients]. *Rev Med Interne.* 2004;25(7):490-3.
 75. Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. *J Eur Acad Dermatol Venereol.* 2008;22(7):779-88.
 76. Canavero S, Bonicalzi V, Massa-Micon B. Central neurogenic pruritus: a literature review. *Acta Neurol Belg.* 1997;97(4):244-7.
 77. Adreev VC, Petkov I. Skin manifestations associated with tumours of the brain. *Br J Dermatol.* 1975;92(6):675-8.
 78. Matsuura J, Kimura A, Kasai T, Yoshida T, Nakagawa M, Mizuno T. A case of neuromyelitis optica with relapse symptoms from paroxysmal pruritus. *Brain Nerve.* 2015;67(8):1057-60.
 79. Misery L. Neuropathic pruritus secondary to brain and spinal cord tumors" in Misery, L., Ständer S. (eds): *Pruritus*. 2nd ed. London: Springer-Verlag; 2016. p. 215-8.
 80. Wolking S, Lerche H, Dihné M. Episodic itch in a case of spinal glioma. *BMC Neurol.* 2013(13): 124.
 81. Savk O, Savk E. Investigation of spinal pathology in notalgia paresthetica. *J Am Acad Dermatol.* 2005;52(6):1085-7.
 82. Savk E. Neurologic itch management. *Curr Probl Dermatol.* 2016;50:116-23.
 83. Wallengren J. Brachioradial pruritus: a recurrent solar dermatopathy. *J Am Acad Dermatol.* 1998;39(5 Pt 1):803-6.
 84. Veien NK, Laurberg G. Brachioradial pruritus: a follow-up of 76 patients. *Acta Derm Venereol* 2011;91(2):183-5.
 85. Mirzoyev SA, Davis MD. Brachioradial pruritus: Mayo Clinic experience over the past decade. *Br J Dermatol.* 2013;169(5):1007-15.
 86. Kwatra SG, Stander S, Bernhard JD, Weisshaar E, Yosipovitch G. Brachioradial pruritus: a trigger for generalization of itch. *J Am Acad Dermatol.* 2013; 68(5):870-3.
 87. Zeidler C, Ständer S. Secondary generalized brachioradial pruritus. An uncommon but easy-to-use differential diagnostic approach to generalized pruritus. *Hautarzt.* 2014;65(1):56-8.
 88. Lee SS, Yosipovitch G, Chan YH, Goh CL. Pruritus, pain, and small nerve fiber function in keloids: a controlled study. *J Am Acad Dermatol.* 2004;51(6):1002-6.
 89. Goutos I. Neuropathic mechanisms in the pathophysiology of burns pruritus: redefining directions for therapy and research. *J Burn Care Res.* 2013;34(1):82-93.
 90. Dhand A, Aminoff MJ. The neurology of itch. *Brain.* 2014;137(Pt 2):313-22.
 91. Mittal A, Srivastava A, Balai M, Khare AK. A study of postherpetic pruritus. *Indian Dermatol Online J.* 2016;7(4):343-4.
 92. Brenaut E, Marcorelles P, Genestet S, Ménard D, Misery L. Pruritus: an underrecognized symptom of small-fiber neuropathies. *J Am Acad Dermatol.* 2015;72(2):328-32.
 93. Mazeh D, Melamed Y, Cholostoy A, Aharonovitch V, Weizman A, Yosipovitch G. Itching in the psychiatric ward. *Acta dermato-venereologica.* 2008;88(2):128-31.
 94. Dalgard F, Lien L, Dalen I. Itch in the community: associations with psychosocial factors among adults. *J Eur Acad Dermatol Venereol.* 2007;21(9):1215-9.
 95. Halvorsen JA, Dalgard F, Thoresen M, Thoresen M, Bjertness E, Lien L. Itch and mental distress: a cross-sectional study among late adolescents. *Acta Derm Venereol.* 2009;89(1):39-44.
 96. Zhao ZQ, Huo FQ, Jeffry J, Hampton L, Demehri S, Kim S, et al. Chronic itch development in sensory neurons requires BRAF signaling pathways. *J Clin Invest.* 2013;123(11):4769-80.
 97. Evers AWM, Schut C, Gieler U, Spillekom-van-Koullil S, van Beugen S. Psychological itch management. In: Szepletowski JC, Weisshaar E, editors. *Itch – Management in Clinical Practice.* Curr Probl Dermatol. 50. Basel: Karger; 2016. p. 64-70.
 98. Craig-Muller SA, Reichenberg JS. The Other Itch That Rashes: a Clinical and Therapeutic Approach to Pruritus and Skin Picking Disorders. *Curr Allergy Asthma Rep.* 2015;15(6):31.
 99. Tomas-Aragones L, Consoli SM, Consoli SG, Poot F, Taube KM, Linder MD, et al. Self-Inflicted Lesions in Dermatology: A Management and Therapeutic Approach - A Position Paper From the European Society for Dermatology and Psychiatry. *Acta Derm Venereol.* 2016.
 100. Lepping P, Huber M, Freudenmann RW. How to approach delusional infestation. *BMJ.* 2015;350:h1328.
 101. Pereira MP, Kremer AE, Mettang T, Ständer S. Chronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment. *Am J Clin Dermatol.* 2016;17(4):337-48.
 102. Reich A, Stander S, Szepletowski JC. Drug-induced pruritus: a review. *Acta Derm Venereol.* 2009;89(3):236-44.
 103. Kaplan AP. Drug-induced skin disease. *J Allergy Clin Immunol.* 1984;74(4 Pt 2):573-9.
 104. Ebata T. Drug-Induced Itch Management. *Curr Probl Dermatol.* 2016;50:155-63.
 105. Metzke D, Reimann S, Szepletowski Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. *Br J Dermatol.* 1997;136(4):553-9.
 106. Beauregard S, Gilchrist BA. A survey of skin problems and skin care regimens in the elderly. *Arch Dermatol.* 1987;123(12):1638-43.
 107. Yalcin B, Tamer E, Toy GG, Oztas P, Hayran M, Alli N. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. *Int J Dermatol.* 2006;45(6):672-6.
 108. Thaipisuttikul Y. Pruritic skin diseases in the elderly. *J Dermatol.* 1998;25(3):153-7.
 109. Sommer F, Hensen P, Bockenholt B, Metzke D, Luger TA, Stander S. Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. *Acta Derm Venereol.* 2007;87(6):510-6.
 110. Weisshaar E, Diepgen TL, Luger TA, Seeliger S, Witteler R, Stander S. Pruritus in pregnancy and childhood--do we really consider all relevant differential diagnoses? *Eur J Dermatol.* 2005;15(5):320-31.
 111. Ambros-Rudolph CM, Mullegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. *J Am Acad Dermatol.* 2006;54(3):395-404.
 112. Holmes RC. Polymorphic eruption in pregnancy. *Sem Dermatol.* 1988;8:18-22.
 113. Girling JC. Obstetric cholestasis. Guideline no 43. London: Royal College of Obstetricians and Gynaecologists (RCOG); 2006.
 114. Roger D, Vaillant L, Fignon A, Pierre F, Dacq Y, Bréchet JF, et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. *Arch Dermatol.* 1994;130:7234-9.
 115. Reyes H, Gonzalez MC, Ribalta J, Aburto H, Matus C, Schramm G, et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. *Ann Intern Med.* 1978;88(4):487-93.
 116. Reyes H, Taboada G, Ribalta J. Prevalence of intrahepatic cholestasis of pregnancy in La Paz, Bolivia. *J Chronic Dis.*

- 1979;32(7):499-504.
117. Clark TJ, Dwarakanath L, Weaver JB. Pruritus in pregnancy and obstetric cholestasis. *Hosp Med*. 1999;60(4):254-60.
118. Saverall C, Sand FL, Thomsen SF. Dermatological diseases associated with pregnancy: pemphigoid gestationis, polymorphic eruption of pregnancy, intrahepatic cholestasis of pregnancy and atopic eruption of pregnancy. *Dermatol Res Pract*. 2015;2015:979635.
119. Ozkan S, Ceylan Y, Ozkan OV, Yildirim SR. Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy. *World J Gastroenterol*. 2015;2(237):7134-41.
120. Metz M, Wahn U, Gieler U, Stock P, Schmitt J, Blume-Peytavi U. Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and paediatricians. *Pediatr Allergy Immunol*. 2013;24(6):527-39.
121. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. *BMJ*. 2006;332(7547):933-8.
122. Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lob-Corzilius T, et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. *Acta Derm Venereol*. 2008;88(3):234-9.
123. Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Dominguez FJ, Echechipia S, et al. Epidemiology of urticaria in Spain. *J Investig Allergol Clin Immunol*. 2004;14:214-20.
124. Lim YL, Chan YH, Yosipovitch G, Greaves MW. Pruritus is a common and significant symptom of acne. *J Eur Acad Dermatol Venereol*. 2008;22(11):1332-6.
125. Reich A, Trybucka K, Tracinska A, Samotij D, Jasiuk B, Srama M, et al. Acne itch: do acne patients suffer from itching? *Acta Derm Venereol*. 2008;88(1):38-42.
126. Wahlgren CF. Children's rating of itch: an experimental study. *Pediatr Dermatol*. 2005;22(2):97-101.
127. Lewis-Jones S. Atopic dermatitis in childhood. *Hosp Med*. 2001; 62:136-43.
128. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. *Br J Dermatol*. 1995;132:942-9.
129. Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. *J Am Acad Dermatol*. 2008;59:234-44.
130. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the dermatitis family impact questionnaire. *Br J Dermatol*. 1998;138:107-13.
131. Wojtowicz-Prus E, Kilis-Pstrusinska K, Reich A, Zachwieja K, Miklaszewska M, Szczepanska M. Chronic Kidney Disease-associated pruritus in children. *Acta Derm Venereol*. 2016.
132. Stumpf A, Ständer S. Neuropathic itch: diagnosis and management. *Dermatol Ther*. 2013;26(2):104-9.
133. Cohen AD, Andrews ID, Medvedovsky E, Peleg R, Vardy DA. Similarities between neuropathic pruritus sites and lichen simplex chronicus sites. *Isr Med Assoc J*. 2014;16(2):88-90.
134. Oaklander AL. Neuropathic itch. *Semin Cutan Med Surg*. 2011;30(2):87-92.
135. Cohen AD, Masalha R, Medvedovsky E, Vardy DA. Brachioradial pruritus: a symptom of neuropathy. *J Am Acad Dermatol*. 2003;48(6):825-8.
136. Savk E, Savk O, Bolukbasi O, Culhaci N, Dikicioglu E, Karaman G, et al. Notalgia paresthetica: a study on pathogenesis. *Int J Dermatol*. 2000;39(10):754-9.
137. Ponticelli C, Bencini PL. Pruritus in dialysis patients: a neglected problem. *Nephrol Dial Transplant*. 1995;10(12):2174-6.
138. Stäubli M. Pruritus—a little known iron-deficiency symptom. *Schweiz Med Wochenschr*. 1981;111(38):1394-8.
139. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. *Br J Dermatol*. 2000;143:969-73.
140. Polat M, Oztas P, Ilhan MN, Yalçın B, Allı N. Generalized pruritus: a prospective study concerning etiology. *Am J Clin Dermatol*. 2008;9(1):39-44.
141. Krause K, Kessler B, Weller K, Veidt J, Chen SC, Martus P, et al. German version of ItchyQoL: validation and initial clinical findings. *Acta Derm Venereol*. 2013;93(5):562-8.
142. Yosipovitch G, Duque MI, Fast K, Dawn AG, Coghill RC. Scratching and noxious heat stimuli inhibit itch in humans: a psychophysical study. *Br J Dermatol*. 2007; 156(4):629-34.
143. Pfab F, Valet M, Sprenger T, Huss-Marp J, Athanasiadis GI, Baurecht HJ, et al. Temperature modulated histamine-itch in lesional and nonlesional skin in atopic eczema - a combined psychophysical and neuroimaging study. *Allergy*. 2010;65(1):84-94.
144. Lisante TA, Nuñez C, Zhang P. Efficacy and safety of an over-the-counter 1% colloidal oatmeal cream in the management of mild to moderate atopic dermatitis in children: a double-blind, randomized, active-controlled study. *J Dermatolog Treat*. 2017;28(7):659-67.
145. Swanbeck G, Rajka G. Antipruritic effect of urea solutions. An experimental and clinical study. *Acta Derm Venereol*. 1970;50(3):225-7.
146. Breternitz M, Kowatzki D, Langenauer M, Elsner P, Fluhr JW. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. *Skin Pharmacol Physiol*. 2008;21(1):39-45.
147. Lindh JD, Bradley M. Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review. *Am J Clin Dermatol*. 2015;16(5):341-59.
148. Yuan C, Wang XM, Guichard A, Tan YM, Qian CY, Yang LJ, et al. N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients. *Clin Interv Aging*. 2014;17(9):1163-9.
149. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. *Pain*. 2003;102(3):283-8.
150. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. *Inflamm Res*. 2003;52(6):238-45.
151. Ständer S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. *Hautarzt*. 2006;57(9):801-7.
152. Szepletowski JC, Szepletowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. *Acta Dermatovenerol Croat*. 2005;13(2):97-103.
153. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). *J Eur Acad Dermatol Venereol*. 2008;22(1):73-82.
154. Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. *J Dtsch Dermatol Ges*. 2010;8(2):88-91.
155. Visse K, Blome C, Phan NQ, Augustin M, Ständer S. Efficacy of Body Lotion Containing N-palmitoylethanolamine in Subjects with Chronic Pruritus due to Dry Skin: A Dermato-cosmetic Study. *Acta Derm Venereol*. 2017;97(5):639-41.
156. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. *Allergy*. 2006;61(3):321-31.
157. EASL. Clinical Practice Guideline: Management of cholestatic liver disease. *J Hepatol*. 2009;51(2):237-67.
158. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. *Allergy*. 2014;69:868-87.
159. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. *J Eur Acad*

- Dermatol Venereol. 2016;30(5):729-47.
160. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol*. 2018;32(5):657-82.
 161. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol*. 2018;32(6):850-78.
 162. Simon D, Bieber T. Systemic therapy for atopic dermatitis. *Allergy*. 2014;69(1):46-55.
 163. Kopecky EA, Jacobson S, Bch MB, Hubley P, Palozzi L, Clarke HM, et al. Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study. *J Burn Care Rehabil*. 2001;22(3):235-42.
 164. Weisshaar E, Forster C, Dotzer M, Heyer G. Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema. *Skin Pharmacol*. 1997;10(4):183-90.
 165. Bauer M, Schwameis R, Scherzer T, Lang-Zwosta I, Nishino K, Zeitlinger M. A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. *J Dermatolog Treat*. 2015;26(4):367-72.
 166. Weisshaar E, Heyer G, Forster C, Hornstein OP, Handwerker HO. [Antipruritic effect of antihistaminic and local anesthetic topical agents after iontophoretic histamine stimulation]. *Hautarzt*. 1996;47(5):355-60.
 167. Layton AM, Cotterill JA. Notalgia paraesthetica--report of three cases and their treatment. *Clin Exp Dermatol*. 1991;16(3):197-8.
 168. Hawro T, Fluhr JW, Mengeaud V, Redoules D, Church MK, Maurer M, et al. Polidocanol inhibits cowhage - but not histamine-induced itch in humans. *Exp Dermatol*. 2014;23(12):922-3.
 169. Young TA, Patel TS, Camacho F, Clark A, Freedman BI, Kaur M, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. *J Dermatolog Treat*. 2009;20(2):76-81.
 170. Gal-Oz A, Rogowski O, Swartzon M, Kivity S. Ethyl chloride as an antipruritic agent: a double-blind placebo-controlled prospective study. *Dermatology* 2010;221(4):373-7.
 171. Welsh AL. *Dermatologist's handbook*. Curtis CA, editor. Springfield, Illinois: Charles C Thomas. Publisher; 1955.
 172. Wallengren J. Tea tree oil attenuates experimental contact dermatitis. *Arch Dermatol Res*. 2011;303(5):333-8.
 173. Yosipovitch G, Szolar C, Hui XY, Maibach H. Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. *Arch Dermatol Res*. 1996;288(5-6):245-8.
 174. Green BG, Schoen KL. Thermal and nociceptive sensations from menthol and their suppression by dynamic contact. *Behav Brain Res*. 2007;176(2):284-91.
 175. Ständer S, Augustin M, Roggenkamp D, Blome C, Heitkemper T, Worthmann AC, et al. Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double-blind, controlled, pilot study in dry skin. *J Eur Acad Dermatol Venereol*. 2017;31(6):1064-8.
 176. Misery L, Santerre A, Batardière A, Hornez N, Nedelec AS, Le Caër F, et al. Real-life study of anti-itching effects of a cream containing menthoxypropanediol, a TRPM8 agonist, in atopic dermatitis patients. *J Eur Acad Dermatol Venereol*. 2018.
 177. Macpherson LJ, Hwang SW, Miyamoto T, Dubin AE, Pataoutian A, Story GM. More than cool: promiscuous relationships of menthol and other sensory compounds. *Mol Cell Neurosci*. 2006;32(4):335-43.
 178. Szolcsanyi J. Forty years in capsaicin research for sensory pharmacology and physiology. *Neuropeptides*. 2004;38(6):377-84.
 179. Wallengren J, Hakanson R. Effects of capsaicin, bradykinin and prostaglandin E2 in the human skin. *Br J Dermatol*. 1992;126(2):111-7.
 180. Knolle E, Zadrazil M, Kovacs GG, Medwed S, Scharbert G, Schemper M. Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. *Pain*. 2013;154(12):2729-236.
 181. Misery L, Erfan N, Castela E, Brenaut E, Lantéri-Minet M, Lacour JP, et al. Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up. *Acta Derm Venereol*. 2015;95(7):864-5.
 182. Zeidler C, Lüling H, Dieckhöfer A, Osada N, Schedel F, Steinke S, et al. Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus? *Br J Dermatol*. 2015;172(6):1669-71.
 183. Lysy J, Sistiery-Ittah M, Israelit Y, Shmueli A, Strauss-Liviatan N, Mindrul V, et al. Topical capsaicin--a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study. *Gut*. 2003;52(9):1323-6.
 184. Wagner T, Roth-Daniek A, Sell A, England J, Kern KU. Capsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from 'real-world' clinical experience. *Pain Manag*. 2012;2(3):239-50.
 185. Wallengren J, Klinker M. Successful treatment of notalgia paraesthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. *J Am Acad Dermatol*. 1995;32(2 Pt 1):287-9.
 186. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH, Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. *J Am Acad Dermatol*. 1986;15(3):504-7.
 187. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. *J Am Acad Dermatol*. 1993;29(3):438-42.
 188. Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA, Pollack VE. Topical capsaicin for treatment of hemodialysis-related pruritus. *J Am Acad Dermatol*. 1992;26(1):91-4.
 189. Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. *Nephron*. 1996;72(4):617-22.
 190. Szeimies RM, Stolz W, Wlotzke U, Korting HC, Landthaler M. Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. *Br J Dermatol*. 1994;131(3):380-2.
 191. Reimann S, Luger T, Metz D. [Topical administration of capsaicin in dermatology for treatment of itching and pain]. *Hautarzt*. 2000;51(3):164-72.
 192. Hoogenberg K, Tupker RA, van Essen LH, Smit AJ, Kaltenberg CG. Successful treatment of ulcerating livedo reticularis with infusions of prostacyclin. *Br J Dermatol*. 1992;127(1):64-6.
 193. Tupker RA, Coenraads PJ, van der Meer JB. Treatment of prurigo nodularis, chronic prurigo and neurodermatitis circumscripta with topical capsaicin. *Acta Derm Venereol*. 1992;72(6):463.
 194. Ständer S, Luger T, Metz D. Treatment of prurigo nodularis with topical capsaicin. *J Am Acad Dermatol*. 2001;44(3):471-8.
 195. Lotti T, Teofoli P, Tsampau D. Treatment of aquagenic pruritus with topical capsaicin cream. *J Am Acad Dermatol*. 1994;30(2 Pt 1):232-5.
 196. Kirby B, Rogers S. Treatment of PUVA itch with capsaicin. *Br J Dermatol*. 1997;137(1):152.
 197. Derry S, Sven-Rice A, Cole P, Tan T, Moore R. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*. 2013;28(2):CD007393.
 198. Elmariah SB, Lerner EA. Topical therapies for pruritus. *Semin Cutan Med Surg*. 2011; 30(2):118-26.
 199. Patel T, Yosipovitch G. The management of chronic pruritus in the elderly. *Skin Therapy Lett*. 2010;15(8):5-9.
 200. Chi CC, Kirtschig G, Aberer W, Gabbud JP, Lipozenčić J,

- Kárpáti S, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. *J Eur Acad Dermatol Venereol*. 2017;31(5):761-73.
201. Zhai H, Frisch S, Pelosi A, Neibart S, Maibach HI. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. *Skin Pharmacol Appl Skin Physiol*. 2000;13(6):352-7.
202. Curto L, Carnero L, López-Aventin D, Travería G, Roura G, Giménez-Arnau AM. Fast itch relief in an experimental model for methylprednisolone aceponate topical corticosteroid activity, based on allergic contact eczema to nickel sulphate. *J Eur Acad Dermatol Venereol*. 2014;28(10):1356-62.
203. Saraceno R, Chiricozzi A, Nisticò SP, Tiberti S, Chimenti S. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. *J Dermatolog Treat*. 2010;21(6):363-6.
204. Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, Butterfass-Bahloul T, et al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. *Dermatology*. 2013;227(4):353-60.
205. Ständer S, Luger TA. [Antipruritic effects of pimecrolimus and tacrolimus]. *Hautarzt*. 2003;54(5):413-7.
206. Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. *Handb Exp Pharmacol*. 2015;226:337-56.
207. Fleischer AB, Jr, Boguniewicz M. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. *J Drugs Dermatol*. 2010;9(5):488-98.
208. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. *J Eur Acad Dermatol Venereol*. 2016;30(5):729-47.
209. Cury Martins J, Martins C, Aoki V, Gois AFT, Ishii HA, da Silva EMK. Topical tacrolimus for atopic dermatitis. *Cochrane Database Syst Rev*. 2015(7):CD009864.
210. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. *Drugs*. 2005;65(6):827-58.
211. Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. *Expert Opin Pharmacother*. 2006;7(14):1967-75.
212. Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, et al. Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Derm*. 2009;60(1):120-4.
213. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. *J Am Acad Dermatol*. 2011;65(1):54-64, e1-2.
214. Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. *J Am Acad Dermatol*. 2011.
215. Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosis. *Cochrane Database Syst Rev*. 2011(2):CD008240.
216. Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. *Expert Rev Clin Pharmacol*. 2012;5(1):91-7.
217. Avgerinou G, Papafragkaki D-K, Nasiopoulou A, Arapaki A, Katsambas A, Stavropoulos PG. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. *J Eur Acad Dermatol Venereol*. 2012;26:762-7.
218. Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. *J Am Acad Dermatol*. 2012;66(2):327-8.
219. Ständer S, Schürmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. *Ther Clin Risk Manag*. 2006;2(2):213-8.
220. Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C, Miranda-Romero A. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. *Br J Dermatol*. 2005;152(4):808-9.
221. Pauli-Magnus C, Klumpp S, Alschner DM, Kuhlmann U, Mettang T. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. *Perit Dial Int*. 2000;20(6):802-3.
222. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. *Nephrol Dial Transplant*. 2004;19(7):1895-901.
223. Duque MI, Yosipovitch G, Fleischer AB, Jr, Willard J, Freedman BI. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. *J Am Acad Dermatol*. 2005;52(3 Pt 1):519-21.
224. Mettang T. Uremic itch management. *Curr Prob Dermatol*. 2016;50:133-41.
225. Ghorbani AR, Feily A, Khalili A, Dormanesh B. Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. *Dermatitis*. 2011;22(3):167-8.
226. Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. *Pediatr Allergy Immunol*. 2015;26(4):306-15.
227. Bornhövd E, Burgdorf WHC, Wallenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. *J Am Acad Dermatol*. 2001;45(5):736-43.
228. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. *Am J Clin Dermatol*. 2013;14(3):163-78.
229. Leslie TA. Itch management in the elderly. *Curr Prob Dermatol*. 2016;50:192-201.
230. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirin on localized circumscribed neurodermatitis. *J Am Acad Dermatol*. 2001;45(6):910-3.
231. Katagiri K. Aspirin and loxoprofen relieve refractory pruritus in patients with prurigo nodularis. *J Dermatol*. 2016;43(9):1104-5.
232. Thomsen JS, Benfeldt E, Jensen SB, Serup J, Menne T. Topically applied aspirin decreases histamine-induced wheal and flare reactions in normal and SLS-inflamed skin, but does not decrease itch. A randomized, double-blind and placebo-controlled human study. *Acta Derm Venereol*. 2002;82(1):30-5.
233. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. *J Am Acad Dermatol*. 1994;31(4):613-6.
234. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. *Arch Dermatol*. 1995;131(12):1403-8.
235. Greenberg JH. Allergic contact dermatitis from topical doxepin. *Contact Dermatitis*. 1995;33(4):281.
236. Shelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. *J Am Acad Dermatol*. 1996;34(1):143-4.
237. Bonnel RA, La Grenade L, Karwoski CB, Beitz JG. Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience. *J Am Acad Dermatol*. 2003;48(2):294-6.
238. Haider SA. Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment. *Br Med J*. 1977;1(6076):1570-2.
239. Stainer R, Matthews S, Arshad SH, McDonald S, Robinson J, Schapira C, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglycate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. *Br J Dermatol*.

- 2005;152(2):334-41.
240. Vieira Dos Santos R, Magerl M, Martus P, Zuberbier T, Church MK, Escribano L, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. *Br J Dermatol*. 2010;162(3):674-6.
241. Leslie TA. *Itch*. Medicine. 2013;41:367-71.
242. Thurmond RL, Kazerouni K, Chaplan SR, Greenspan AJ. Antihistamines and Itch. *Handb Exp Pharmacol*. 2015;226:257-90.
243. Leslie TA. *Antihistamines*. Abingdon: Taylor and Francis Group; 2015.
244. Gray SL, Anderson ML, Dublin Sea. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med*. 2015;175:401-7.
245. Leslie TA, Grattan CH. Antihistamines, sodium cromoglicate, and leukotriene receptor antagonists. In: Arden-Jones M, Hampton P, Vleugels RA, editors. *Handbook of Dermatology Treatment*. London: JP Medical Ltd; 2017. p. 64-7 (in press).
246. O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. *Dermatol Ther*. 2005;18(4):333-40.
247. Millington GWM, Collins A, Lovell CRea. British Association of Dermatologists' guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis. *BJD*. 2018;178:34-60.
248. Gokdemir G, Doruk T. Treatment of generalized pruritus: comparison of narrowband ultraviolet-B with oral cetirizine. *J Eur Acad Dermatol Venereol* 2011;25:1484-5.
249. Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. *Cochrane Database Syst Rev*. 2014(11):CD006137.
250. Mullol J, Bousquet J, Bachert C, Canonica GW, Giménez-Arnau A, Kowalski ML, et al. Update on rupatadine in the management of allergic disorders. *Allergy* 2015;70:1-24.
251. Karppinen A, Brummer-Korvenkontio H, Reunala T, Izquierdo I. Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy. *J Eur Acad Dermatol Venereol*. 2012;26:919-22.
252. Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Y. Wd. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. *Ther Clin Risk Manag*. 2016;12:585-97.
253. Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z, Jupiter A, Mattered U, Weisshaar E. Oral H1 antihistamines as monotherapy for eczema. *Cochrane Database Syst Rev*. 2013;2:CD007770.
254. He A, Feldman SR, Fleischer AB. An assessment of the use of antihistamines in atopic dermatitis. *J Amer Acad Dermatol*. 2018;79(1):92-6.
255. Domagala A, Szepietowski J, Reich A. Antihistamines in the treatment of pruritus in psoriasis. *Adv Dermatol Allergol*. 2017;34(5):457-63.
256. Potter P, Mitha E, Barkai L, Mezei G, Santamaria E, Izquierdo I, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. *Pediatr Allergy Immunol*. 2016;27:55-61.
257. Gonzalez-Estrada A, Geraci SA. Allergy medications during pregnancy. *Am J Med Sci*. 2016;352(3):326-31.
258. Powell RJ, Leech SC, Till S, Huber PAJ, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. *Clin Exp Allergy*. 2015;45:547-65.
259. Belloni Fortina A, Fontana E. Update on antihistamine treatment for chronic urticaria in children. *Curr Treat Options Allergy*. 2014; 1:287.
260. Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. *Eur J Clin Pharmacol*. 1986;31(3):277-80.
261. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health Technol Assess*. 2000;4(37):1-191.
262. Tey HL, Yosipovitch G. Targeted treatment of pruritus - a look into the future. *Br J Dermatol*. 2011;165(1):5-17.
263. Engelhardt H, Smits RA, Leurs R, Haaksma E, de Esch IJ. A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. *Curr Opin Drug Discov Devel*. 2009; 12:628-43.
264. Thurmond RL. The histamine H4 receptor: from orphan to the clinic. *Front Pharmacol*. 2015;6:65.
265. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Stander S. [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series]. *Hautarzt*. 2009;60(7):564-8.
266. Amir Khanlou S, Rashedi A, Taherian J, Hafezi AA, Parsaei S. Comparison of Gabapentin and Ketotifen in Treatment of Uremic Pruritus in Hemodialysis Patients. *Pak J Med Sci*. 2016;32(1):22-6.
267. Vessal G, Sagheb MM, Shilian S, Jafari P, Samani SM. Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. *Nephrol Dial Transplant*. 2010;25(5):1541-7.
268. Streit M, Von Felbert V, Braathen LR. [Pruritus sine marte-ria. Pathophysiology, diagnostic assessment and therapy]. *Hautarzt*. 2002;53(12):830-49.
269. Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. *Int J Dermatol*. 2010; 49(1):1-11.
270. Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. *Clin Immunol* 2015;158(1):1-7.
271. Nattkemper LA, Martinez-Escala ME, Gelman AB, Singer EM, Rook AH, Guitart J, et al. Cutaneous T-Cell Lymphoma and Pruritus: the Expression of IL-31 and its Receptors in the Skin. *Acta Derm Venereol*. 2016.
272. Fjellner B, Hagermark O. Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine. *Arch Dermatol Res*. 1982;274(1-2):29-37.
273. Phan NQ, Lotts T, Antal A, Bernhard JD, Stander S. Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review. *Acta Derm Venereol*. 2012.
274. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. *Ann Intern Med*. 1995;123(3):161-7.
275. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. *J Am Acad Dermatol*. 1999;41(3 Pt 1):431-4.
276. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. *Gastroenterology*. 1992;102(2):544-9.
277. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. *Gastroenterology*. 1997;113(4):1264-9.
278. Phan NQ, Bernhard JD, Luger TA, Stander S. Systemic kappa opioid receptor (KOR) agonists in the treatment of chronic pruritus: a review. *Acta Derm Venereol*. 2012:in press.
279. Banerji D, Fox R, Seleznick M, Lockey R. Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis. *J Allergy Clin Immunol*. 1988;81:252 (Abstr.).
280. Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. *J Am Acad Dermatol*. 1989;21(1):135-6.
281. Ghura HS, Patterson AD, Carmichael AJ. Naltrexone in the treatment of renal itch. *Br J Dermatol*. 1998;139 (suppl 51):139.
282. Legroux-Crespel E, Clèdes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. *Dermatology*. 2004;208(4):326-30.
283. Malekzad F, Arbabi M, Mohtasham N, Toosi P, Jaberian M, Mohajer M, et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. *J Eur Acad Dermatol Venereol*. 2009;23(8):948-50.
284. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor

- agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. *Nephrol Dial Transplant*. 2010;25(4):1251-7.
285. Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. *Am J Nephrol*. 2012;36(2):175-83.
286. Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. *Hepato Res*. 2016.
287. Misery L. Gabapentin in dermatology. *Dermatology*. 2005;211(2):79-80.
288. Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. *J Pain Symptom Manage*. 2004;28(4):396-411.
289. Mendham JE. Gabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study. *Burns*. 2004;30(8):851-3.
290. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. *Nephrol Dial Transplant*. 2004;19(12):3137-9.
291. Naini AE, Harandi AA, Khanbabapour S, Shadidi S, Seirafivan S, Mosheni M. Gabapentin: a promising drug for the treatment of uremic pruritus. *Saudi J Kidney Dis Transpl*. 2007;18(3):378-81.
292. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. *Hepatology*. 2006;44(5):1317-23.
293. Vila T, Gommer J, Scates AC. Role of gabapentin in the treatment of uremic pruritus. *Ann Pharmacother*. 2008;42(7):1080-4.
294. Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. *Ren Fail*. 2009;31(2):85-90.
295. Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus. *J Am Acad Dermatol*. 2016;75(3):619-25.
296. Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. *Eur J Dermatol*. 2006;16(3):311-2.
297. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. *J Am Acad Dermatol*. 2006;55(3):543-4.
298. Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, et al. Efficacy of pregabalin in the management of cetuximab-related itch. *J Pain Symptom Manage*. 2006;32(5):397-8.
299. Ehrchen J, Stander S. Pregabalin in the treatment of chronic pruritus. *J Am Acad Dermatol*. 2008;58(2 Suppl):S36-7.
300. Rayner H, Baharani J, Smith S, Suresh V, Dasgupta I. Uraemic pruritus: relief of itching by gabapentin and pregabalin. *Nephron Clin Pract*. 2012;122(3-4):75-9.
301. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. *J Ren Care*. 2010;36(4):180-5.
302. Yue J, Jiao S, Xiao Y, Ren W, Zhao T, Meng J. Comparison of pregabalin with ondansetron in treatment of uremic pruritus in dialysis patients: a prospective, randomized, double-blind study. *Int Urol Nephrol*. 2015;47(1):161-7.
303. Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S. Treatment of prurigo nodularis with pregabalin. *J Clin Pharm Ther*. 2013;38(1):16-8.
304. Foroutan N, Etminkan A, Nikvarz N, Shojai Shahrokh Abadi M. Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. *Hemodial Int*. 2017;21(1):63-71.
305. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. *J Am Soc Nephrol*. 2018;29(7):1970-9.
306. Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: A systematic review. *J Am Acad Dermatol*. 2017;77(6):1068-73.e7.
307. Brasileiro LEE, Dayanna Patricia de Carvalho Barreto DP, Nunes EA. Psychotropics in different causes of itch: systematic review with controlled studies. *An Bras Dermatol*. 2016;9(6):791-8.
308. Kaur R, Sinha VR. Antidepressants as antipruritic agents: A review. *Eur Neuropsychopharmacol*. 2018;28(3):341-52.
309. Schut C, Grossmann S, Gieler U, Kupfer J, Yosipovitch G. Contagious itch: what we know and what we would like to know. *Front Hum Neurosci* 2015;11(9):57.
310. Paus R, Schmelz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. *J Clin Invest*. 2006;116(5):1174-86.
311. Schneider G, Driesch G, Heuft G, Evers S, Luger TA, Stander S. Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. *Clin Exp Dermatol*. 2006;31(6):762-7.
312. Wang XD, Yang G, Bai Y, Feng YP, LI H. The behavioral study on the interactive aggravation between pruritus and depression. *Brain Behav*. 2018;8(6):e00964.
313. Szepletowski JC, Reszke R. Psychogenic Itch Management. *Curr Probl Dermatol*. 2016;50:124-32.
314. Zyllicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. *J Pain Symptom Manage*. 2003;26(6):1105-12.
315. Heisig M, Salomon J, Szepletowski JC. Chronic pruritus in an elderly patient with dementia successfully treated with paroxetine. *Przegl Dermatol*. 2012;99:620-4.
316. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. *Blood*. 2002;99(7):2627.
317. Zyllicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. *J Pain Symptom Manage*. 1998;16(2):121-4.
318. Weisshaar E. Intractable chronic pruritus in a 67-year-old man. *Acta Derm Venereol*. 2008;88(5):488-90.
319. Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. *Psychother Psychosom*. 2000;69(3):165-6.
320. Mazzatenta C, Peonia G, Martini P. Pruritus induced by interruption of paroxetine therapy. *Br J Dermatol*. 2004;150(4):787.
321. Ständer S, Bockenholt B, Schurmeyer-Horst F, Weishaupt C, Heuft G, Luger TA, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. *Acta Derm Venereol*. 2009;89(1):45-51.
322. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. *Hepatology*. 2007;45(3):666-74.
323. Thébaut A, Habes D, Gottrand F, Rivet C, Cohen J, Debray D, et al. Sertraline as an additional treatment for cholestatic pruritus in children. *J Pediatr Gastroenterol Nutr*. 2016.
324. Shakiba M, Sanadgol H, Azmoude HR, Mashhadi MA, Sharifi H. Effect of sertraline on uremic pruritus improvement in ESRD patients. *Int J Nephrol*. 2012;2012:363901.
325. Chan KY, Li CW, Wong H, Yip T, Chan ML, Cheng HW, et al. Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients. *J Palliat Med*. 2013;16(8):966-70.
326. Pakfetrat M, Malekmakan L, Hashemi N, Tadayon T. Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. *Hemodial Int*. 2018;22(1):103-9.
327. Shohrati M, Tajik A, Harandi AA, Davoodi SM, Akmasi M. Comparison of hydroxyzine and doxepin in treatment of pruritus due to sulfur mustard. *Skinmed*. 2007;6(2):70-2.
328. Savin JA, Paterson WD, Adam K, Oswald I. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. *Arch Dermatol*. 1979;115(3):313-5.
329. Davis MP, Frandsen JR, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. *J Pain Symptom Manage*. 2003;25(3):288-91.
330. Lee JJ, Girouard SD, Carlberg VM, Mostaghimi A. Efficacy

- tive use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse. *BMJ Support Palliat Care*. 2016;2016(1):119-21.
331. Wachholz PA, Masuda PY, Pinto ACVD, Martelli ACC. Impact of drug therapy on brachioradial pruritus. *An Bras Dermatol*. 2017;92(2):281-2.
 332. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. *Pain*. 1995;61(1):33-7.
 333. Schworer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. *Clin Investig*. 1993;71(8):659-62.
 334. Andrews PA, Quan V, Ogg CS. Ondansetron for symptomatic relief in terminal uraemia. *Nephrol Dial Transplant*. 1995;10(1):140.
 335. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. *Lancet*. 1999;354(9176):397.
 336. Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. *N Engl J Med*. 1994;330(21):1540.
 337. Albares MP, Betlloch I, Guijarro J, Vergara G, Pascual JC, Botella R. Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. *Br J Dermatol*. 2003;148(2):376-7.
 338. Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. *Lancet*. 1993;341(8855):1277.
 339. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. *Eur J Gastroenterol Hepatol*. 1998;10(10):865-70.
 340. O'Donohue JW, Haigh C, Williams R. Ondansetron in the treatment of cholestasis: a randomised controlled trial. *Gastroenterology*. 1997;112:A1349.
 341. Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. *Pharmacotherapy*. 1996;16(5):958-60.
 342. Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. *Anesthesiology*. 1999;90(2):432-6.
 343. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. *Eur J Anaesthesiol*. 2001;18(6):346-57.
 344. Balaskas EV, Bamihis GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. *Nephron*. 1998;78(4):395-402.
 345. Weisshaar E, Dunker N, Rohl FW, Gollnick H. Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. *Exp Dermatol*. 2004;13(5):298-304.
 346. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. *Am J Kidney Dis*. 2000;35(5):827-31.
 347. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. *Br J Dermatol*. 2003;148(2):314-7.
 348. Daly BM, Shuster S. Antipruritic action of thalidomide. *Acta Derm Venereol*. 2000;80(1):24-5.
 349. van den Broek H. Treatment of prurigo nodularis with thalidomide. *Arch Dermatol*. 1980;116(5):571-2.
 350. Arrese JE, Dominguez-Soto L, Hojyo-Tomoka MT, Vega-Memije E, Cortes-Franco R, Guevara E, et al. Effectors of inflammation in actinic prurigo. *J Am Acad Dermatol*. 2001;44(6):957-61.
 351. Winkelman RK, Connolly SM, Doyle JA, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. *Acta Derm Venereol*. 1984;64(5):412-7.
 352. Johnke H, Zachariae H. Thalidomide treatment of prurigo nodularis. *Ugeskr Laeger*. 1993;155(38):3028-30.
 353. Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of Thalidomide and Lenalidomide in the treatment of refractory prurigo nodularis. *Dermatol Ther*. 2016;6:397-411.
 354. Ferrandiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. *Dermatology*. 1997;195(4):359-61.
 355. Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. *Arch Dermatol*. 2004;140(7):845-9.
 356. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. *Nephron*. 1994;67(3):270-3.
 357. Gaspari A. Thalidomide neurotoxicity in dermatological patients: the next "STEP". *J Invest Dermatol*. 2002;119(5):987-8.
 358. Lowney AC, McAleer MA, Kelly S, McQuillan RJ. Thalidomide therapy for pruritus in the palliative setting – a distinct subset of patients in whom the benefit may outweigh the risk. *Pain Symptom Manag*. 2014;48:e3-e5.
 359. Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. *Arch Dermatol*. 2012;148(7):794-6.
 360. van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. *Arch Dermatol*. 1987;123(2):166-7.
 361. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. *Acta Derm Venereol*. 1990;70(4):323-9.
 362. Viegas LP, Ferreira MB, Kaplan AP. The maddening itch: an approach to chronic urticaria. *J Investig Allergol Clin Immunol*. 2014;24(1):1-5.
 363. Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. *Br J Dermatol*. 1995;132(5):795-9.
 364. Siepmann D, Luger TA, Stander S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. *J Dtsch Dermatol Ges*. 2008;6(11):941-6.
 365. Wallengren J. Prurigo: diagnosis and management. *Am J Clin Dermatol*. 2004;5(2):85-95.
 366. Teofoli P, De Pita O, Frezzolini A, Lotti T. Antipruritic effect of oral cyclosporin A in essential senile pruritus. *Acta Derm Venereol*. 1998;78(3):232.
 367. Calikoglu E, Anadolu R. Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. *Acta Derm Venereol*. 2002;82(5):380-2.
 368. Dawn A, Yosipovitch G. Treating itch in psoriasis. *Dermatol Nurs*. 2006;18(3):227-33.
 369. Simon D. Systemic therapy of atopic dermatitis in children and adults. *Curr Probl Dermatol*. 2011;41:156-64.
 370. Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. *Clin Exp Dermatol*. 2014;39(4):468-73.
 371. Klejtman T, Beylot-Barry M, Joly P, Richard MA, Debarbieux S, Misery L, et al. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. *J Eur Acad Dermatol Venereol*. 2018;32(3):437-40.
 372. Kibsgaard L, Bay B, Deleuran M, Vestergaard C. A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and comorbidities in 98 bullous pemphigoid patients admitted to a tertiary centre. *Acta Derm Venereol*. 2015;95(3):307-11.
 373. Maley A, Swerlick RA. Azathioprine treatment of intractable pruritus: A retrospective review. *J Am Acad Dermatol*. 2015;73(3):439-43.
 374. Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. *Acta Derm Venereol*. 2015;95(7):866-7.
 375. Keaney TC, Bhutani T, Sivanesan P, Bandow GD, Weinstein SB, Cheung LC, et al. Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis. *J Am Acad Dermatol*. 2012;67(4):636-41.
 376. Lee FJ, Frankum BS, Katelaris CH. Poor efficacy of oral

- tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series. *Australas J Dermatol.* 2012;53(4):295-7.
377. Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. *Support Care Cancer.* 2010;18(9):1229-30.
378. Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continous. *J Am Acad Dermatol.* 2012;66(1):e14-5.
379. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdts S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. *Br J Dermatol.* 2011;164(3):665-7.
380. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. *N Engl J Med.* 2010;363(4):397-8.
381. Ständer S, Luger TA. NK-1 antagonists and itch. *Handb Exp Pharmacol.* 2015;226:237-55.
382. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. *PLoS One.* 2010;5(6):e10968.
383. Lönn Dahl L, Holst M, Bradley M, Killasli H, Heilborn J, Hall MA, et al. Substance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis. *Acta Derm Venereol.* 2018;98(3):324-28.
384. Ohanyan T, Schoepke N, Eirefelt S, Hoey G, Koopmann W, Hawro T, et al. Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. *Acta Derm Venereol.* 2018;98(1):26-31.
385. Tsianakas A, Zeidler C, Riepe C, Borowski M, Forner C, Gerss J, et al. Aprepitant in histamine-refractory chronic nodular prurigo: a multicentre, randomized, double-blind, placebo-controlled, cross-over, phase- II trial (APREPRU). *Acta Derm Venereol.* 2019; 99:379-385.
386. Yosipovitch G, Ständer S, Kerby MB, Larrick JW, Perlman AJ, Schnipper EF, et al. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. *J Am Acad Dermatol.* 2018;78(5):882-91.e10.
387. Ständer S, Kwon P, Hirman J, Perlman AJ, Weisshaar E, Metz M, et al. Serlopitant reduced pruritus in patients with Prurigo Nodularis in a phase 2, randomized, placebo-controlled trial. *Am J Acad Dermatol.* 2019 <https://doi.org/10.1016/j.jaad.2019.01.052>.
388. McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. *Drugs.* 2014;74:1693-9.
389. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Giménez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med.* 2013;368:924-35.
390. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. *J Invest Dermatol.* 2015;135:67-75.
391. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. *J Allergy Clin Immunol.* 2013;132:101-9.
392. Thaci D, Simpson EL, Bieber T, Blauvelt A, Papp K, Soong W, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose ranging phase 2b trial. *The Lancet.* 2016;387:40-52.
393. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). *J Am Acad Dermatol.* 2015;73(1):37-49.
394. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). *Br J Dermatol.* 2015;173(6):1387-99.
395. Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Gonçalves J, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. *Acta Derm Venereol.* 2016;96(4):514-20.
396. Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, et al. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. *J Eur Acad Dermatol Venereol.* 2018.
397. Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. *J Am Acad Dermatol.* 2016;75(6):1156-61.
398. Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. *Int J Dermatol.* 2016;55(4):401-7.
399. Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. *J Eur Acad Dermatol Venereol.* 2018.
400. Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Burge R, et al. Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. *Acta Derm Venereol.* 2018;98(98-102).
401. Théréne C, Brenaut E, Barnette T, Misery L. Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis. *J Invest Dermatol.* 2018;138(1):38-45.
402. Shibuya T, Honma M, Iinuma S, Iwasaki T, Ishida-Yamamoto A. Persistent pruritus in psoriatic patients during administration of biologics. *J Dermatol.* 2018.
403. Lee JH, Park CK, Chen G, Han Q, Xie RG, Liu T, et al. A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. *Cell.* 2014;157:1393-404.
404. Hettrick HH, O'Brien K, Laznick H, Sanchez J, Gorga D, Nagler W, et al. Effect of transcutaneous electrical nerve stimulation for the management of burn pruritus: a pilot study. *J Burn Care Rehabil.* 2004;25(3):236-40.
405. Mohammad Ali BM, Hegab DS, El Saadany HM. Use of transcutaneous electrical nerve stimulation for chronic pruritus. *Dermatol Ther.* 2015;28(4):210-5.
406. Belgrade MJ, Solomon LM, Lichter EA. Effect of acupuncture on experimentally induced itch. *Acta Derm Venereol.* 1984;64:129-33.
407. Lundeberg T, Bondesson L, Thomas M. Effect of acupuncture on experimentally induced itch. *Br J Dermatol.* 1987;117:771-7.
408. Pfab F, Huss-Marp J, Gatti A, Fugin J, Athanasiadis GI, Irnich D, et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. *Allergy.* 2010; 65:903-10.
409. Carlsson CP, Wallengren J. Therapeutic and experimental therapeutic studies on acupuncture and itch: review of the literature. *J Eur Acad Dermatol Venereol.* 2010;24(9):1013-6
410. Stellan A. Neurogenic pruritus: an unrecognised problem? A retrospective case series of treatment by acupuncture. *Acupunct Med.* 2002;20(4):186-90.
411. Che-Yi C, Wen CY, Min-Tsung K, Chiu-Ching H. Acupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus. *Nephrol Dial Transplant.* 2005;20(9):1912-5.
412. Badiie Aval S, Ravanshad Y, Azarfara A, Mehrad-Majd H, Torabi S, Ravanshad S. A Systematic Review and Meta-analysis of Using Acupuncture and Acupressure for Uremic

- Pruritus. *Iran J Kidney Dis.* 2018;12(2):78-83.
413. Pfab F, Schalock PC, Napadow V, Athanasiadis GI, Huss-Marp J, Ring J. Acupuncture for allergic disease therapy—the current state of evidence. *Expert Rev Clin Immunol.* 2014;10:831-41.
 414. Pfab F, Huss-Marp J, Gatti A, Fuqin J, Athanasiadis GI, Irrnich D, et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. *Allergy.* 2010;65(7):903-10.
 415. Gibson W, Wand BM, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. *Cochrane Database Syst Rev.* 2017;14(9):CD011976.
 416. Fjellner B, Hägermark O. Transcutaneous nerve stimulation and itching. *Acta Derm Venereol.* 1978;58(2):131-4.
 417. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. *Pain.* 1997;71(1):49-55.
 418. Nilsson HJ, Psouni E, Carstam R, Schouenborg J. Profound inhibition of chronic itch induced by stimulation of thin cutaneous nerve fibres. *J Eur Acad Dermatol Venereol.* 2004;18(1):37-43.
 419. Wallengren J, Sundler F. Cutaneous field stimulation in the treatment of severe itch. *Arch Dermatol.* 2001;137(10):1323-5.
 420. Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. *Dermatol Ther.* 2005;18(4):344-54.
 421. Steinhoff M, Cevikbas F, Ikoma A, Berger TG. Pruritus: management algorithms and experimental therapies. *Semin Cutan Med Surg.* 2011;30(2):127-37.
 422. Kamata Y, Tominaga M, Takamori K. Itch in Atopic Dermatitis Management. *Curr Probl Dermatol.* 2016;50:86-93.
 423. Tominaga M, Tengara S, Kamo A, Ogawa H, Takamori K. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. *J Dermatol Sci.* 2009;55(1):40-6.
 424. Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. *Br J Dermatol.* 2014;170(3):501-13.
 425. Majoie IM, Oldhoff JM, van Weelden H, Laaper-Ertmann M, Bousema MT, Sigurdsson V, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. *Journal of the American Academy of Dermatology.* 2009;60(1):77-84.
 426. Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of itch in atopic dermatitis. *Semin Cutan Med Surg.* 2011;30(2):71-86.
 427. Der-Petrossian M, Seeber A, Honigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. *Br J Dermatol.* 2000;142(1):39-43.
 428. Baltas E, Csoma Z, Bodai L, Ignacz F, Dobozy A, Kemeny L. Treatment of atopic dermatitis with the xenon chloride excimer laser. *J Eur Acad Dermatol Venereol.* 2006;20(6):657-60.
 429. Gambichler T, Hyun J, Sommer A, Stucker M, Altmeyer P, Kreuter A. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. *Clin Exp Dermatol.* 2006;31(3):348-53.
 430. Rombold S, Lobisch K, Katzer K, Graziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. *Photodermatol Photoimmunol Photomed.* 2008;24(1):19-23.
 431. Szepletowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. *Med Hypotheses.* 2002;58(2):167-70.
 432. Wallengren J, Sundler F. Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres. *Acta Derm Venereol.* 2004;84(2):111-5.
 433. Su LN, Xu X, Tang L, Yu N, Ding YF. UVA1 phototherapy in the treatment of palmoplantar pustulosis: a pilot prospective study. *Lasers Med Sci.* 2016;31(8):1641-3.
 434. Zanardelli M, Kovacevic M, McCoy J, Wang X, Goren A, Lotti T. Management of chronic pruritus with a UV filtering topical cream. *Dermatol Ther.* 2016;29(2):101-3.
 435. Grattan CEH, Radia DH. *Mastocytosis.* In: C. Griffiths JB, T. Bleiker, R. Chalmers, & D. Creamer, editor. *Rook's textbook of dermatology.* Ninth edition ed. Chichester, West Sussex; Hoboken, NJ: John Wiley & Sons Inc.; 2016.
 436. Saltzer EJ, Grove G. Relief from uremic pruritus: a therapeutic approach. *Cutis.* 1975;16:298-9.
 437. Gilchrist BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Relief of uremic pruritus with ultraviolet phototherapy. *N Engl J Med.* 1977;297(3):136-8.
 438. Ada S, Seckin D, Budakoglu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. *J Am Acad Dermatol.* 2005;53(1):149-51.
 439. Seckin D, Demircay Z, Akin O. Generalized pruritus treated with narrowband UVB. *Int J Dermatol.* 2007;46(4):367-70.
 440. Ko MJ, Yang JY, Wu HY, Hu FC, Chen SI, Tsai PJ, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. *Br J Dermatol.* 2011;165(3):633-9.
 441. Hsu MM, Yang CC. Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. *Br J Dermatol.* 2003;149(4):888-9.
 442. Berger TG, Steinhoff M. Pruritus and renal failure. *Semin Cutan Med Surg.* 2011;30(2):99-100.
 443. Leslie TA. Itch. *Medicine.* 2013;41(7):367-71.
 444. Decock S, Roelandts R, Steenberghe W, Laleman W, Cassiman D, Verslype C, et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. *J Hepatol.* 2012;57(3):637-41.
 445. Baldo A, Sammarco E, Plaitano R, Martinelli V, Monfrecola. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. *Br J Dermatol.* 2002;147(5):979-81.
 446. Kaptanoglu AF, Oskay T. Ultraviolet B treatment for pruritus in Hodgkin's lymphoma. *J Eur Acad Dermatol Venereol.* 2003;17(4):489-90.
 447. Jahn S, von Kobyletzki G, Behrens S, Röchling A, Altmeyer P, Kerscher M. Erfolgreiche Behandlung des aquagenen Pruritus mit PUVA-Bad-Photochemotherapie. *Z Hautkr.* 1997;72:821-24.
 448. Holme SA, Anstey AV. Aquagenic pruritus responding to intermittent photochemotherapy. *Clin Exp Dermatol.* 2001;26(1):40-1.
 449. Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-Pedreno P, Aliaga A. Treatment of aquagenic urticaria with PUVA and astemizole. *J Am Acad Dermatol.* 1997;36(1):118-9.
 450. Menage HD, Norris PG, Hawk JL, Graves MW. The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. *Br J Dermatol.* 1993;129(2):163-5.
 451. Xifra A, Carrascosa JM, Ferrandiz C. Narrow-band ultraviolet B in aquagenic pruritus. *Br J Dermatol.* 2005;153(6):1233-4.
 452. Lim HW, Vallurupalli S, Meola T, Soter NA. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. *J Am Acad Dermatol.* 1997;37(3 Pt 1):414-7.
 453. Singh F, Rudikoff D. HIV-associated pruritus: etiology and management. *Am J Clin Dermatol.* 2003;4(3):177-88.
 454. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. *Br J Dermatol.* 2008;159(4):931-5.
 455. Lee E, Koo J, Berger TG. UVB phototherapy and skin cancer risk: a review of the literature. *Int J Dermatol.* 2005;44(5):355-60.
 456. Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johanneson A, Berne B, et al. PUVA and cancer risk: the Swedish follow-up study. *Br J Dermatol.* 1999;141(1):108-12.
 457. Stern RS, Study PFu. The risk of melanoma in association with long-term exposure to PUVA. *J Am Acad Dermatol.* 2001;44(5):755-61.
 458. Berger TG, Shive M, Harper GM. Pruritus in the older pa-

- tient: a clinical review. *Jama*. 2013; 310:2443-50.
459. Leslie TA. Itch Management in the Elderly. *Curr Probl Dermatol*. 2016;50:192-201.
 460. Valdes-Rodriguez R, Stull C, Yosipovitch G. Chronic pruritus in the elderly: pathophysiology, diagnosis and management. *Drugs Aging*. 2015;32:201-15.
 461. Gutman AB, Kligman AM, Sciacca J, James WD. Soak and smear: a standard technique revisited. *Arch Dermatol*. 2005;141:1556-9.
 462. Pazyar N, Yaghoobi R, Kazerouni A, Feily A. Oatmeal in dermatology: a brief review. *Indian J Dermatol Venereol Leprol*. 2012;78:142-5.
 463. Lavery MJ, Stull C, Kinney MO, Yosipovitch G. Nocturnal Pruritus: The Battle for a Peaceful Night's Sleep. *Int J Mol Sci*. 2016; 17:425.
 464. Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after material exposure to topical corticosteroids. A UK population-based cohort study. *JAMA Dermatol*. 2013;149:1274-80.
 465. Chi CC, Wang WH, Wojnarowska F, Kiritschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. *Cochrane Database Syst Rev* 2015(10):CD007346.
 466. Treudler R. Allergische Erkrankungen bei Schwangeren. *Hautarzt*. 2010;61:1027-33.
 467. Murase JE, Heller MM, Butler DC. Safety of dermatological medications in pregnancy and lactation: Part I. Pregnancy. *J Am Acad Dermatol*. 2014;70:401-14.
 468. Berth-Jones J, Pollock I, Heran RM, Lewis-Jones S, Goodfield M, Griiffiths CE, et al. A randomised, controlled trial of a 4% cutaneous emulsion of sodium cromoglicate in treatment of atopic dermatitis in children. *J Dermatol Treat*. 2015;26:291-6.
 469. Draelos ZD, Stein Gold LF, Murrell DF, Hughes MH, Zane LT. Post Hoc analysis of the effect of crisaborole topical ointment 2% on atopic dermatitis: Associated pruritus from phase 1 and 2 clinical studies. *J Drugs Dermatol*. 2016;15(2):172-6.
 470. Church MK, Weller K, Stock P, Maurer M. Chronic spontaneous urticaria in children: itching for insight. *Pediatr Allergy Immunol*. 2011;22:1-8.
 471. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? *J Eur Acad Dermatol Venereol*. 2011;25(6):727-9.
 472. Rosenbaum MS, Ayllon T. The behavioral treatment of neurodermatitis through habit-reversal. *Behav Res Ther*. 1981;19(4):313-8.
 473. Gieler U, Kupfer J, Niemeier V, Brosig B, Stangier U. Atopic eczema prevention programs - a new therapeutic concept for secondary prevention. *Dermatol Psychosom*. 2000;1:138-47.
 474. Staab D, von Rueden U, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. *Pediatr Allergy Immunol*. 2002;13(2):84-90.
 475. Stangier U, Ehlers A, Gieler U. Predicting long-term outcome in group treatment of atopic dermatitis. *Psychother Psychosom*. 2004;73(5):293-301.
 476. Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al. Psychological and educational interventions for atopic eczema in children. *Cochrane Database Syst Rev*. 2007.
 477. Evers AW, Duller P, de Jong EM, Otero ME, Verhaak CM, van der Valk PG, et al. Effectiveness of a multidisciplinary itchy-coping training programme in adults with atopic dermatitis. *Acta Derm Venereol*. 2009;89(1):57-63.
 478. Bathe A, Mattered U, Dewald M, Grande T, Weisshaar E. Educational multidisciplinary training programme for patients with chronic pruritus. *Acta Derm Venereol*. 2009;89(5):498-501.
 479. Hoegl L, Fichter M, Plewig G. [Inpatient behavioral medicine in chronic skin diseases]. *Hautarzt*. 1998;49(4):270-5.
 480. Lange S, Zschocke I, Langhardt S, Amon U, Augustin M. [Effects of combined dermatological and behavioural medicine therapy in hospitalized patients with psoriasis and atopic dermatitis]. *Hautarzt*. 1999;50(11):791-7.
 481. Gupta MA. Evaluation and treatment of "psychogenic" pruritus and self-excoriation. *J Am Acad Dermatol*. 1995;32(3):532-3.
 482. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. *CNS Drugs*. 2001;15(5):351-9.
 483. Phillips LG, Robson MC. Pruritus in burns. Comments from Detroit Receiving Hospital, Detroit, Michigan. *J Burn Care Rehabil*. 1988;9(3):308-9.
 484. Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. *CNS Spectr*. 2002;7(6):453-60, 63.
 485. Van Beugen S, Ferwerda M, Hoeve D, Rovers MM, Spillekom-van Koulik S, van Middendorp H, et al. Internet-based cognitive behavioral therapy for patients with chronic somatic conditions: a meta-analytic review. *J Med Internet Res*. 2014;16(3):e88.
 486. Bundy DG, Morawski LF, Lazorick S, Bradbury S, Karnachi K, Suresh GK. Education in Quality Improvement for Pediatric Practice: an online program to teach clinicians. *Acad Pediatr*. 2014;14(5):517-25.
 487. Chen YC, Chiu WT, Wu MS. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. *Am J Kidney Dis*. 2006;48(1):69-76.
 488. Gilchrist BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. *Ann Intern Med*. 1979;91(1):17-21.
 489. Mahmudpour M, Roozbeh J, Raiss Jalali GA, Pakfetrat M, Ezzat Zadeegan S, Sagheb MM. Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. *Iran J Kidney Dis*. 2017;11(1):50-5.
 490. Rosner MH. Cromolyn sodium: a potential therapy for uremic pruritus? *Hemodial Int*. 2006;10(2):189-92.
 491. De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. *N Engl J Med*. 1992;326(15):969-74.
 492. Francos GC, Kauh YC, Gittlen SD, Schulman ES, Besarab A, Goyal S, et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. *Int J Dermatol*. 1991;30(12):884-9.
 493. Gouliis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. *Lancet*. 1999;354(9184):1053-60.
 494. Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study). *Medicine (Baltimore)*. 2016;95(40):e494.
 495. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. *Gastroenterology*. 1988;94(2):488-93.
 496. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. *J Hepatol*. 2002;37(6):717-22.
 497. McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. *J Hepatol*. 1994;21(4):496-9.
 498. Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. *N Engl J Med*. 2018;378(23):2171-81.
 499. Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. *Drug Des Devel Ther*. 2015;9:5407-19.
 500. Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, et al. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis

- and refractory pruritus? A post-marketing, single-arm, prospective study. *J Gastroenterol*. 2018.
501. Raiford DS. Pruritus of chronic cholestasis. *QJM*. 1995;88(9):603-7.
 502. Wait RP, Daneshmend TK, Fellows IW, Toghill PJ. Effect of stanazolol on itching in primary biliary cirrhosis. *Br Med J (Clin Res Ed)*. 1988;296(6622):607.
 503. Kraut RY. Treatment of pruritus in a palliative care patient with low-dose paroxetine: a case report. *J Med Case Rep*. 2017;11(1):280.
 504. Fleischer AB, Jr. The clinical management of itching. New York, London: Parthenon Publishing; 2000.
 505. Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. *Am J Gastroenterol*. 2001;96(5):1563-70.
 506. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. *Dig Dis Sci*. 2004;49(1):1-4.
 507. Appleby VJ, Hutchinson JM, Davies MH. Safety and efficacy of long-term nasobiliary drainage to treat intractable pruritus in cholestatic liver disease. *Frontline Gastroenterol*. 2015;6(4):252-4.
 508. Doria C, Mandala L, Smith J, Vitale CH, Lauro A, Gruttadauria S, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. *Liver Transpl*. 2003;9(4):437-43.
 509. Mullhaupt B, Kullak-Ublick GA, Ambuhl PM, Stocker R, Renner EL. Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. *Hepatol Res*. 2003;25(4):442-6.
 510. Bellmann R, Feistritz C, Zoller H, Graziadei IW, Schwaighofer H, Propst A, et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. *ASAIO J*. 2004;50(4):387-91.
 511. Acevedo Ribo M, Moreno Planas JM, Sanz Moreno C, Rubio Gonzalez EE, Rubio Gonzalez E, Boullosa Grana E, et al. Therapy of intractable pruritus with MARS. *Transplant Proc*. 2005;37(3):1480-1.
 512. Montero JL, Pozo JC, Barrera P, Fraga E, Costan G, Dominguez JL, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). *Transplant Proc*. 2006;38(8):2511-3.
 513. Bellmann R, Graziadei IW, Feistritz C, Schwaighofer H, Stellaard F, Sturm E, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. *Liver Transpl*. 2004;10(1):107-14.
 514. Neuberger J. Liver Transplantation for Cholestatic Liver Disease. *Curr Treat Options Gastroenterol*. 2003;6:113-21.
 515. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *New England Journal of Medicine*. 2016;0(0):null.
 516. Brune A, Metzger D, Luger TA, Ständer S. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. *Hautarzt*. 2004;55(12):1130-6.
 517. Fjellner B, Hagermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. *Acta Derm Venereol*. 1979;59(6):505-12.
 518. Easton P, Galbraith PR. Cimetidine treatment of pruritus in polycythemia vera. *N Engl J Med*. 1978;299(20):1134.
 519. Weick JK, Donovan PB, Najean Y, Dresch C, Pisciotto AV, Cooperberg AA, et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. *Arch Intern Med*. 1982;142(2):241-2.
 520. Fitzsimons EJ, Dagg JH, McAllister EJ. Pruritus of polycythaemia vera: a place for pizotifen? *Br Med J (Clin Res Ed)*. 1981;283(6286):277.
 521. Chanarin I, Szur L. Letter: Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine. *Br J Haematol*. 1975;29(4):669-70.
 522. Swerlick RA. Photochemotherapy treatment of pruritus associated with polycythemia vera. *J Am Acad Dermatol*. 1985;13(4):675-7.
 523. Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. *Ann Hematol*. 1996;73(2):91-3.
 524. Tinégate H, McLelland J. Transcutaneous electrical nerve stimulation may improve pruritus associated with haematological disorders. *Clin Lab Haematol*. 2002;24(6):389-90.
 525. de Wolf JT, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E. Alpha-interferon for intractable pruritus in polycythaemia vera. *Lancet*. 1991;337(8735):241.
 526. Muller EW, de Wolf JT, Egger R, Wijermans PW, Huijgens PC, Halie MR, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. *Br J Haematol*. 1995;89(2):313-8.
 527. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. *Am J Hematol*. 1993;43(4):316-8.
 528. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. *Br J Haematol*. 1996;92(1):55-9.
 529. Shelley WB, Shelley ED. Aquagenia: noradrenergic pain induced by bathing and responsive to clonidine. *J Am Acad Dermatol*. 1998;38(2 Pt 2):357-8.
 530. Wolf R, Krakowski A. Variations in aquagenic pruritus and treatment alternatives. *J Am Acad Dermatol*. 1988;18(5 Pt 1):1081-3.
 531. Steinman HK, Greaves MW. Aquagenic pruritus. *J Am Acad Dermatol*. 1985;13(1):91-6.
 532. Koh MJ, Chong WS. Aquagenic pruritus responding to combined ultraviolet A/narrowband ultraviolet B therapy. *Photodermatol Photoimmunol Photomed*. 2009;25(3):169-70.
 533. Nosbaum A, Pecquet C, Bayrou O, Amsler E, Nicolas JF, Bérard F, et al. Treatment with propranolol of 6 patients with idiopathic aquagenic pruritus. *J Allergy Clin Immunol*. 2011;128(5):1113.
 534. Cao T, Yong AA, Tan KB, Tey HL. Idiopathic aquagenic pruritus: pathogenesis and effective treatment with atenolol. *Dermatol Ther*. 2015;28(3):118-21.
 535. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ -opioid receptor antagonists: a review. *J Am Acad Dermatol*. 2010;63(4):680-8.

